CN113959912A - Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof - Google Patents
Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof Download PDFInfo
- Publication number
- CN113959912A CN113959912A CN202010702062.2A CN202010702062A CN113959912A CN 113959912 A CN113959912 A CN 113959912A CN 202010702062 A CN202010702062 A CN 202010702062A CN 113959912 A CN113959912 A CN 113959912A
- Authority
- CN
- China
- Prior art keywords
- substituted
- group
- unsubstituted
- compound
- ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title claims abstract description 85
- 238000001514 detection method Methods 0.000 title claims abstract description 74
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 65
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 272
- 210000001772 blood platelet Anatomy 0.000 claims abstract description 187
- 125000003277 amino group Chemical group 0.000 claims abstract description 153
- 210000004369 blood Anatomy 0.000 claims abstract description 137
- 239000008280 blood Substances 0.000 claims abstract description 137
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 100
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 55
- 238000004220 aggregation Methods 0.000 claims abstract description 45
- 230000002776 aggregation Effects 0.000 claims abstract description 41
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 62
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 62
- -1 ammonium ions Chemical class 0.000 claims description 48
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 44
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 30
- 229910006069 SO3H Inorganic materials 0.000 claims description 26
- 230000003287 optical effect Effects 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 23
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 21
- 235000019270 ammonium chloride Nutrition 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 210000003743 erythrocyte Anatomy 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 230000002934 lysing effect Effects 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 239000007850 fluorescent dye Substances 0.000 claims description 12
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 8
- 238000005336 cracking Methods 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000004254 Ammonium phosphate Substances 0.000 claims description 6
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 6
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 6
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 6
- 150000001450 anions Chemical class 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000879 imine group Chemical group 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims description 5
- 238000009534 blood test Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000010186 staining Methods 0.000 claims description 5
- XZXYQEHISUMZAT-UHFFFAOYSA-N 2-[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol Chemical compound CC1=CC=C(O)C(CC=2C(=CC=C(C)C=2)O)=C1 XZXYQEHISUMZAT-UHFFFAOYSA-N 0.000 claims description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 4
- 239000001099 ammonium carbonate Substances 0.000 claims description 4
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 4
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims description 4
- 229940107816 ammonium iodide Drugs 0.000 claims description 4
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 4
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 3
- WWILHZQYNPQALT-UHFFFAOYSA-N 2-methyl-2-morpholin-4-ylpropanal Chemical compound O=CC(C)(C)N1CCOCC1 WWILHZQYNPQALT-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 3
- 239000000908 ammonium hydroxide Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 3
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- ZETCGWYACBNPIH-UHFFFAOYSA-N azane;sulfurous acid Chemical compound N.OS(O)=O ZETCGWYACBNPIH-UHFFFAOYSA-N 0.000 claims description 2
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 103
- 210000000601 blood cell Anatomy 0.000 abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000035484 reaction time Effects 0.000 abstract description 4
- 239000006166 lysate Substances 0.000 description 44
- 239000003085 diluting agent Substances 0.000 description 29
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 28
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- NGGXACLSAZXJGM-UHFFFAOYSA-N n-(diaminomethylidene)acetamide Chemical compound CC(=O)N=C(N)N NGGXACLSAZXJGM-UHFFFAOYSA-N 0.000 description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000003146 anticoagulant agent Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000003204 osmotic effect Effects 0.000 description 14
- 108091006146 Channels Proteins 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 108090000190 Thrombin Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 229960005188 collagen Drugs 0.000 description 13
- 229960004072 thrombin Drugs 0.000 description 13
- 238000004820 blood count Methods 0.000 description 12
- 239000000975 dye Substances 0.000 description 12
- 125000001841 imino group Chemical group [H]N=* 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229940127219 anticoagulant drug Drugs 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 9
- 108010081391 Ristocetin Proteins 0.000 description 9
- 230000010100 anticoagulation Effects 0.000 description 9
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229950004257 ristocetin Drugs 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108010049003 Fibrinogen Proteins 0.000 description 7
- 102000008946 Fibrinogen Human genes 0.000 description 7
- 229940012952 fibrinogen Drugs 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 150000002357 guanidines Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229960005323 phenoxyethanol Drugs 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 4
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000022 bacteriostatic agent Substances 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 125000000542 sulfonic acid group Chemical group 0.000 description 4
- 125000001302 tertiary amino group Chemical group 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 102100023472 P-selectin Human genes 0.000 description 3
- 239000000980 acid dye Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 2
- XXZJETFEIRYFCD-UHFFFAOYSA-N 2-(aminomethyl)propane-1,3-diamine Chemical compound NCC(CN)CN XXZJETFEIRYFCD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RQJDUEKERVZLLU-UHFFFAOYSA-N 4-Hydroxybenzylamine Chemical compound NCC1=CC=C(O)C=C1 RQJDUEKERVZLLU-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229950000244 sulfanilic acid Drugs 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- HERSSAVMHCMYSQ-UHFFFAOYSA-N 1,8-diazacyclotetradecane-2,9-dione Chemical compound O=C1CCCCCNC(=O)CCCCCN1 HERSSAVMHCMYSQ-UHFFFAOYSA-N 0.000 description 1
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HEAHMJLHQCESBZ-UHFFFAOYSA-N 2,5-diaminobenzenesulfonic acid Chemical compound NC1=CC=C(N)C(S(O)(=O)=O)=C1 HEAHMJLHQCESBZ-UHFFFAOYSA-N 0.000 description 1
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 1
- HQMLIDZJXVVKCW-UHFFFAOYSA-N 2-aminopropanamide Chemical compound CC(N)C(N)=O HQMLIDZJXVVKCW-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- PDCMTKJRBAZZHL-UHFFFAOYSA-N 5-aminobenzene-1,3-diol Chemical compound NC1=CC(O)=CC(O)=C1 PDCMTKJRBAZZHL-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101710085664 Gene 55 protein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XXACTDWGHQXLGW-UHFFFAOYSA-M Janus Green B chloride Chemical compound [Cl-].C12=CC(N(CC)CC)=CC=C2N=C2C=CC(\N=N\C=3C=CC(=CC=3)N(C)C)=CC2=[N+]1C1=CC=CC=C1 XXACTDWGHQXLGW-UHFFFAOYSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 1
- 229910017677 NH4H2 Inorganic materials 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- AWZSFOZTECCDOO-UHFFFAOYSA-N [Na].CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC Chemical compound [Na].CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC AWZSFOZTECCDOO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- OBESRABRARNZJB-UHFFFAOYSA-N aminomethanesulfonic acid Chemical compound NCS(O)(=O)=O OBESRABRARNZJB-UHFFFAOYSA-N 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- UKFWSNCTAHXBQN-UHFFFAOYSA-N ammonium iodide Chemical compound [NH4+].[I-] UKFWSNCTAHXBQN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-O azanium;hydron;hydroxide Chemical compound [NH4+].O VHUUQVKOLVNVRT-UHFFFAOYSA-O 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- UETLMBWMVIQIGU-UHFFFAOYSA-N calcium azide Chemical compound [Ca+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] UETLMBWMVIQIGU-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 102000017941 granulin Human genes 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- JYVNDCLJHKQUHE-UHFFFAOYSA-N hydroxymethyl acetate Chemical compound CC(=O)OCO JYVNDCLJHKQUHE-UHFFFAOYSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 229940018564 m-phenylenediamine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- MIOKKLXTDJFGIV-UHFFFAOYSA-M sodium;n-methylcarbamate Chemical compound [Na+].CNC([O-])=O MIOKKLXTDJFGIV-UHFFFAOYSA-M 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N2015/0092—Monitoring flocculation or agglomeration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/018—Platelets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Ecology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a detection method and a reagent for resisting platelet aggregation interference and application thereof. The detection method comprises the following steps: subjecting a blood sample to a treatment for preventing and/or eliminating platelet aggregation in the blood sample with a disaggregating agent, wherein the disaggregating agent includes at least one selected from the group consisting of a compound having an amino group and a compound containing an ammonium ion; and detecting the blood sample treated by the depolymerizing agent by using a blood analyzer so as to obtain at least detection information of the white blood cells after eliminating the blood cell aggregation interference. The depolymerizing agent has depolymerization effect on various platelet aggregation conditions, can depolymerize platelets in a short time, does not need additional conditions such as water bath temperature control and reaction time prolonging, can conveniently eliminate platelet aggregation in a sample, and obtains accurate blood cell detection parameters.
Description
Technical Field
The present invention relates to blood detection, and more particularly to a method for detecting leukocytes which are free from the interference of false platelet aggregation in the presence of the platelets, and a reagent therefor.
Background
In the analysis of blood cells, the pseudoaggregation of platelets can lead to erroneous blood cell counts and classifications, which in turn can lead to misdiagnosis and treatment of the patient. We can easily confuse false platelet aggregation with certain life-threatening diseases such as heparin-induced in vivo platelet aggregation (HIP), Disseminated Intravascular Coagulation (DIC), or make wrong treatment decisions such as wrong medication, improper platelet infusion to patients, and even splenectomy. The causes of the pseudoaggregation of platelets are numerous and complex, with common causes including: ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia (EDTA-PTCP), multiple anticoagulant-dependent platelet aggregation, platelet satellite phenomenon, hypercholesterolemia and hypertriglyceridemia, cold platelet aggregation caused by low temperature environment, unsmooth blood collection, aggregation caused by the material of an anticoagulation tube, and the like. The mechanism of platelet pseudo-aggregation has been studied only rarely, and much focus has been on EDTA-PTCP. EDTA is a widely used anticoagulant in clinic identified by the International Commission on standardization of hematology (ICSH), and the pseudoaggregation of platelets caused by EDTA was first reported in 1969, and probably the main reason is that EDTA-dependent antiplatelet antibodies exist in blood of EDTA-PTCP patients, and when the blood is mixed with EDTA anticoagulant in vitro, the antibodies can recognize adhesion receptor glycoprotein IIb-IIIa (Gpiib-IIIa) on platelet membranes, and cause the expression of platelet aggregation activation antigens, such as granulin protein 140(GMP140, alias CD62P or P-selectin), type III lysosomal glycoprotein (Gp55, alias CD63) and thrombin sensitive protein, and further activate tyrosine kinase, thus leading to platelet aggregation.
The false aggregation of the blood platelets not only causes the error of related clinical parameters of the blood platelets, but also influences the accuracy of other clinical parameters of blood cells, and brings adverse effects on clinical diagnosis and treatment. Therefore, finding and eliminating platelet aggregation in blood samples is a problem that has been desired to be solved in extracorporeal blood tests.
Currently, several solutions have been clinically adopted to eliminate or reduce bloodPlatelets pseudo-aggregate. For example, a blood sample with pseudoaggregated platelets is heated to 37 degrees celsius while shaking for a period of time, or additives are added to the blood sample to prevent platelet aggregation. Such as anticoagulants (e.g., sodium citrate, heparin sodium, ACD, CTAD, CPT, CaCl)2And mixtures of sodium heparin, etc.); platelet count diluent (containing a mixture of sodium azide, calcium azide, sodium fluoride and the like); antiplatelet drugs (added within 10 minutes after blood draw); aminoglycoside antibiotics (such as amikacin and kanamycin, added within 1 hour after blood collection, but are effective only on a fraction of samples).
These methods and agents for preventing platelet aggregation in ex vivo blood samples either result in complex testing procedures, less than optimal platelet disaggregation or aggregation due to only partial causes, often requiring re-bleeding and formulation of specific disaggregating agents. In practice, it is also necessary to observe microscopic observations of the platelets after addition of the additive to determine whether the disaggregation effect is sufficient for blood analysis. If necessary, the action time is prolonged in an ice bath or a water bath so as to ensure the depolymerization effect of the platelets.
Therefore, a platelet disaggregation method and reagent with simple operation and good universality are still needed in the in vitro blood detection to obtain accurate leukocyte detection parameters.
Disclosure of Invention
Accordingly, the present invention is directed to a method for detecting leukocytes, which is capable of eliminating the interference of platelet pseudo-aggregation, and is simple and easy to perform without requiring additional steps, changing the existing detection steps and conditions, and not affecting the detection. Another object of the present invention is to provide a reagent for leukocyte measurement suitable for use in the method of the present invention, which contains a substance capable of preventing and/or eliminating platelet aggregation, which does not interfere with other reagents used in blood measurement, reacts rapidly, and does not require additional reaction conditions.
According to a first aspect of the present invention, there is provided a method of detecting leukocytes which are interfered with by anti-platelet aggregation, the method comprising:
subjecting a blood sample to a treatment for preventing and/or eliminating platelet aggregation in the blood sample with a disaggregating agent, wherein the disaggregating agent includes at least one selected from the group consisting of a compound having an amino group and a compound containing an ammonium ion; and
and detecting the blood sample treated by the depolymerizing agent by using a blood analyzer so as to obtain at least detection information of the white blood cells.
According to a particular embodiment, the compound having an amino group is selected from the group consisting of compounds represented by the following formula (I) and salts thereof: R1-NH-R2(I)
Wherein R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, SO, and R1 and R2 are not both H3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkylaryl, substituted or unsubstituted C7-14 arylalkyl, -C (O) -Q1 and-C (O) -O-Q2,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkaryl, or substituted or unsubstituted C7-14 aralkyl;
q2 is H, substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkaryl, or substituted or unsubstituted C7-14 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, halogen, -CN, -C (O) -O-P3, -O-C1-16 alkyl, -O-C6-10 aryl, -O-C7-14 alkylaryl, -O-C7-14 arylalkyl, -C (O) -C1-16 alkyl, -C (O) -C6-10 aryl, -C (O) -C7-14 alkylaryl, -C (O) -C7-14 arylalkyl and-C (O) -NP1P2, wherein said-O-C1-16 alkyl, -O-C6-10 aryl, -O-C7-14 alkylaryl, -O-C7-14 arylalkyl, -C (O) -C1-16 alkyl, -C (O) -C6-10 aryl, -C (O) -C7-14 alkaryl and-C (O) -C7-14 aralkyl each being unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. Halogen, -CN, -COOH and-C (O) NH2Group ofIs substituted by the group (a) in (b),
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-16 alkyl, C6-10 aryl, C7-14 alkaryl and C7-14 aralkyl, wherein said C1-16 alkyl, C6-10 aryl, C7-14 alkaryl and C7-14 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. Halogen, -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
More specifically, in the formula (I), R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, -SO, provided that R1 and R2 are not simultaneously H3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, substituted or unsubstituted C7-10 aralkyl, -C (O) -Q1 and-C (O) -O-Q2,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
q2 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, -CN, -C (O) -O-P3, -O-C1-10 alkyl, -O-C6-10 aryl, -O-C7-10 alkylaryl, -O-C7-10 arylalkyl, and-C (O) -NP1P2, wherein each of said-O-C1-10 alkyl, -O-C6-10 aryl, -O-C7-10 alkylaryl, and-O-C7-10 arylalkyl is unsubstituted or further substituted with at least one moiety selected from the group consisting of-NH, -CN, -C (O) -O-P3, -O-C1-10 alkyl, -O-C6-aryl, and-O-C7-10 arylalkyl2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of;
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl, wherein the C1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl are each unsubstituted or furtherAt least one step is selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
Still further, in the formula (I), R1 and R2 are the same or different and each is independently a group selected from the group consisting of H, -SO, provided that R1 and R2 are not simultaneously H3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, substituted or unsubstituted C7-10 aralkyl, -C (O) -Q1 and-C (O) -O-H,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, -CN, -C (O) -O-H and-C (O) -NP1P 2;
p1 and P2 are each independently a group selected from the group consisting of: H. c1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl, wherein said C1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
According to the invention, the total number of primary amino groups, secondary amino groups and/or imino groups of the compound of formula (I) is 1-20.
According to the present invention, the compound having an amino group has an amino pKa value of 1 to 16, preferably 4 to 14.
Preferably, the compound having an amino group has an amino pKa value equal to or less than the pH value of the depolymerization agent.
In the present invention, the concentration of the compound having an amino group in the depolymerization agent is 1 to 50mmol/L, preferably 2 to 20 mmol/L.
According to another embodiment, the ammonium ion containing compound comprises an anion selected from the group consisting of chloride, bromide, iodide, hydroxide, phosphate, hydrogen phosphate, dihydrogen phosphate, nitrate, hydrogen sulfide, thiocyanate, sulfate, hydrogen sulfate, sulfite, hydrogen sulfite, carbonate, bicarbonate, formate, acetate, oxalate, propionate, malonate, citrate, and combinations thereof.
More specifically, the compound containing an ammonium ion is at least one selected from the group consisting of ammonium chloride, ammonium bromide, ammonium iodide, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium nitrate, ammonium thiocyanate, ammonium hydrogen sulfite, ammonium oxalate, ammonium hydroxide, ammonium hydrogen sulfate and ammonium hydrogen carbonate.
According to the invention, the concentration of the compound containing ammonium ions in the depolymerizing agent is 1 to 50mmol/L, preferably 2 to 20 mmol/L.
According to one embodiment, the depolymerizing agent comprises at least one compound having an amino group and at least one compound containing an ammonium ion.
In this embodiment, the total concentration of the at least one compound having an amino group and the at least one compound containing an ammonium ion in the depolymerization agent is 2 to 50mmol/L, preferably 2 to 20mmol/L, and more preferably 2 to 10 mmol/L.
In this embodiment, the molar ratio of the at least one compound having an amino group and the at least one compound containing an ammonium ion is in the range of 10:1 to 1:10, preferably 4:1 to 1: 4.
According to the detection method of the present invention, the pH value when the blood sample is treated with the depolymerization agent is at least 3.0, preferably at least 7.0, and more preferably 7.5 to 11.0.
According to one embodiment, the blood analyzer comprises an impedance detector, the blood sample is hemolyzed with a red blood cell lysing agent before the detection, and the method comprises the steps of:
and detecting the blood sample treated by the depolymerizing agent and the red blood cell cracking agent by using an impedance detector in a blood analyzer to obtain an electric signal of particles in the blood sample, and further obtaining a white blood cell detection parameter after aggregation interference is eliminated.
According to another embodiment, the blood analyzer comprises an optical detector, the blood sample is stained with a fluorescent dye and hemolyzed with a red blood cell lysing agent, and the method comprises: detecting the blood sample treated by the depolymerizing agent, the fluorescent dye and the red blood cell cracking agent by using an optical detector in a blood analyzer to obtain at least two optical signals of particles in the blood sample so as to obtain detection information of white blood cells;
preferably, the at least two light signals are selected from the group consisting of fluorescence intensity signals, forward scattered light intensity signals, and side scattered light intensity signals.
According to a second aspect of the present invention, there is provided a reagent for detecting leukocytes in an in vitro blood test, wherein the reagent comprises at least one selected from the group consisting of a compound having an amino group and a compound containing an ammonium ion, a red blood cell lysing agent, a buffer and an osmotic pressure regulating agent, and optionally a fluorescent dye and/or a surfactant, wherein the concentration of the compound having an amino group is 1 to 50mmol/L, and the concentration of the compound containing an ammonium ion is 1 to 50 mmol/L.
According to a particular embodiment, the compound having an amino group is selected from the group consisting of compounds represented by the following formula (I) and salts thereof:
R1-NH-R2 (I)
wherein the compound of formula (I) is as defined above.
In the present invention, the total number of primary amino groups, secondary amino groups and/or imino groups contained in the compound of formula (I) may be 1 to 20.
In the present invention, the compound having an amino group may have an amino pKa value of 1 to 16, preferably 4 to 14.
According to a preferred embodiment, the compound having an amino group has an amino pKa value equal to or lower than the pH value of the reagent.
In the reagent, the concentration of the compound having an amino group may be 2 to 20 mmol/L.
According to a particular embodiment, the compound containing ammonium ions is as defined above.
In the reagent of the present invention, the concentration of the compound containing ammonium ions may be 2 to 20 mmol/L.
According to one embodiment, the reagent comprises at least one compound having an amino group and at least one compound containing an ammonium ion.
In this embodiment, the total concentration of the at least one compound having an amino group and the at least one compound containing an ammonium ion in the reagent is 2 to 50mmol/L, preferably 2 to 20mmol/L, and more preferably 2 to 10 mmol/L.
In this embodiment, the molar ratio of the at least one compound having an amino group and the at least one compound containing an ammonium ion is in the range of 10:1 to 1:10, preferably 4:1 to 1: 4.
The reagent according to the invention has a pH value of at least 3.0, preferably at least 7.0, more preferably of 7.5 to 11.
According to a third aspect of the present invention there is provided the use of a platelet disaggregating reagent in the detection of leukocytes, wherein the platelet disaggregating reagent is as defined above for the disaggregating agent.
In the application, the pH value of the platelet depolymerizing agent is at least 3.0, preferably at least 7.0, and more preferably 7.5-11.0.
According to a particular embodiment, the platelet disaggregating agent further comprises a red blood cell lysing agent, a buffer and an osmolality adjusting agent, and optionally a fluorescent dye and/or a surfactant.
In the blood detection method of the present invention, the depolymerization of the aggregated platelets by the depolymerizing agent can depolymerize the platelets in a short time without additional conditions such as temperature control by water bath and prolonged reaction time, and thus the existing detection procedure does not need to be changed, and the method is suitable for any blood analyzer. Accurate leukocyte detection parameters can be obtained from the blood sample after depolymerization treatment. Moreover, the reagent for detecting the leucocytes has no adverse effect on other conventional reagents for detection, can respectively obtain better depolymerization effect under various platelet aggregation conditions, can conveniently eliminate the false aggregation of the platelets in a sample, and can obtain accurate detection parameters of the leucocytes.
Drawings
FIG. 1 shows a schematic of the mechanism of disaggregation and repolymerization of aggregated platelets by a compound having an amino group;
fig. 2 shows a three-dimensional scattergram of particles in a blood sample obtained in an optical detection apparatus, in which optical information characteristics of aggregated platelets and disaggregated platelets are shown, respectively;
FIG. 3 is a graph showing the disaggregation effect of a compound having an amino group on aggregated platelets at various ambient pH conditions;
FIG. 4 is a graph showing the disaggregation effect of compounds with different amino pKa values on aggregated platelets at pH 9.5;
figure 5 shows a graph of the induction of platelet aggregation in blood samples with ADP at different final concentrations as a function of time;
figure 6 shows a graph of the disaggregation effect of a compound with amino groups on ADP-induced platelet aggregation at different concentrations as a function of time;
FIG. 7 shows a graph of THR induction of platelet aggregation in blood samples at different final concentrations over time;
figure 8 shows a graph of the disaggregation effect of a compound having an amino group on THR-induced platelet aggregation at different concentrations over time;
FIG. 9 shows a graph of the induction of platelet aggregation in blood samples by COL at different final concentrations as a function of time;
FIG. 10 is a graph showing the disaggregation effect of a compound having an amino group on COL-induced platelet aggregation at different concentrations as a function of time;
FIG. 11 shows a graph of the induction of platelet aggregation in blood samples by RIS at different final concentrations as a function of time;
fig. 12 shows a graph of the disaggregation effect of a compound with an amino group on platelet aggregation induced at different concentrations over time;
figure 13 shows the disaggregation effect of various ammonium ion-containing compounds on ADP-induced aggregated platelets at different concentrations;
FIG. 14 shows the disaggregation effect of 1-acetylguanidine and ammonium chloride, each and in combination, on aggregated platelets at different concentrations;
FIG. 15 shows a three-dimensional scattergram of a blood sample before and after induced aggregation using a conventional lysate and a lysate containing a compound having an amino group to detect leukocytes in the sample in an optical detection apparatus;
FIG. 16 shows a three-dimensional scattergram of a blood sample before and after induced aggregation for detecting leukocytes in the sample in an optical detection device using a conventional lysate and a lysate containing ammonium chloride;
FIG. 17 shows a three-dimensional scattergram of a blood sample before and after induced aggregation for detecting leukocytes in the sample using a conventional lysate and a lysate containing a combination of a compound having an amino group and a compound having an ammonium ion group in an optical detection apparatus;
FIG. 18 is a graph showing a comparison of the disaggregation effect of a conventional diluent and a diluent containing a compound having an amino group against a sample showing pseudoaggregation of platelets in the clinic;
fig. 19 shows a graph comparing the disaggregation effect of a conventional diluent and a diluent containing ammonium chloride in the clinic against samples showing pseudoaggregation of platelets.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings and specific examples, and it is apparent that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.
It is to be noted that, in the present invention, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a method or article comprising a list of elements does not include only the elements explicitly recited, but also includes other elements not explicitly listed or inherent to the method or article of manufacture. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other related elements in a method or apparatus that comprises the element.
The term "amino" as used herein refers to primary and/or secondary amino groups, unless otherwise specified, and does not include tertiary amino groups.
The "compound having an amino group" as used herein refers to a compound having at least one amino group (primary and/or secondary amino group) unless otherwise specified. The compounds may optionally also contain tertiary amino groups and/or imine groups, especially also optionally contain imine groups.
The inventors have surprisingly found that a class of compounds containing amino groups has a significant disaggregation effect on the pseudo-aggregation of platelets caused by different causes, and that platelet aggregation can be eliminated after about 30s by adding only a small amount of the substance to a solution of a blood sample to be tested, without additional heating or cooling, and without a long action time. Thus, the present invention provides the use of such substances to prevent and/or eliminate platelet aggregation in a blood sample. The disaggregated pseudoaggregated platelets can not only obtain the real number of platelets in a blood sample so as to provide a reliable reference basis for clinical decision, but also eliminate the influence of larger particles formed by aggregation of platelets on the classification and counting of other blood cells.
Without wishing to be bound by theory, the disaggregation principle of the amino group-containing compound of the present invention on pseudoaggregated platelets supposedly is that the amino/imino groups in the compound bind to the phosphatidylserine membrane of platelets in solution and are hydrogen-bonded to the carbonyl ester groups (-O-c (O) -) on the phosphatidylserine membrane (see fig. 1, which illustrates the disaggregation principle of the amino group-containing compound). Thus, the amino group of the compound bound to the phosphatidylserine membrane blocks the calcium channel, preventing the influx of calcium ions. It is known that platelet aggregation requires the involvement of calcium ion influx, and therefore, such compounds disaggregate aggregated platelets by preventing calcium ion influx through amino groups. As the pH gradually decreases, the amino group on the compound is protonated. Although the specific cause is not clear, it is presumed that the protonated amino group of the compound is no longer bound to the carbonyl group of the phosphatidylserine membrane through hydrogen bonding, calcium ions are re-flowed into the blood cells, and platelet aggregation is caused. In theory, in addition to the tertiary amino group, a primary, secondary or imino group having at least one hydrogen atom attached to the N atom has some platelet depolymerization function.
Further, the present inventors have found that the larger the number of amino groups/imino groups in the compound having an amino group, the better the depolymerization effect. In addition, the depolymerization effect of the primary amino group, the secondary amino group and the imino group alone is reduced in order. Generally, a compound having a strong hydrophilicity is higher in depolymerization effect than a compound having a weak hydrophilicity. Hydrophilic substituents, such as hydroxyl, carboxyl, amido, sulfonic acid, etc., have substantially no effect on the depolymerization effect of the amino/imino groups, and in some cases (such as hydroxyl, polyhydroxy) even facilitate depolymerization. This may be related to the fact that these groups increase the water solubility of the compound and the affinity to the phosphatidylserine layer membrane. Hydrocarbyl groups, such as alkyl, aryl, and the like, do not significantly affect platelet depolymerization as long as they do not affect the compound's water solubility to a certain extent. Hydrophobic groups, such as ester (-C (O) -O-), carbonyl (-C (O) -) will reduce the depolymerization effect to some extent.
Therefore, compounds having a hydroxyl group, a carboxyl group, a sulfonic acid group, such as alcamines, amino acids, sulfonic acids, and the like are more preferable. In addition, substances having a plurality of amino groups and/or imino groups are also preferable, such as guanidines, short peptides, and the like. Preferably, the amino group-containing compound has at least one primary or secondary amino group, preferably 1 to 20 primary, secondary and/or imino groups. The amino compound preferably has at least one primary amino group, and more preferably has 1 to 4 primary amino groups.
According to the above-presumed mechanism, the compound having an amino group is depolymerized with the amino group therein being present in a deprotonated form in a solution. The amino/imino groups in different compounds differ in their ability to bind hydrogen ions in solution. This ability to bind/dissociate hydrogen ions can be expressed in terms of the dissociation constant pKa.
The compound having an amino group in solution has the following formula:
to obtain a suitable platelet disaggregation effect, the amino groups of the compound should have a suitable pKa value. For compounds having multiple amino/imine groups, the pKa of an amino group as used herein refers to the first dissociation constant, i.e., the pKa of the first amino or imine group that dissociates hydrogen ions.
Generally, the amino group of the compound should have a pKa value of 1 to 16, preferably 1 to 14, more preferably 4 to 14.
In addition, for the same compound, when the pKa value of the amino group in the compound is smaller than the pH value of the solution, the depolymerization capability is improved. According to the principle of disaggregation of aggregated platelets by the above-mentioned compounds, it can be understood that as the pH is gradually increased, the equilibrium of binding and dissociation of amino groups in the compounds with hydrogen ions in the solution is shifted in the direction of dissociation, and more amino groups are deprotonated, and thus more amino groups are bound to the phosphatidylserine membrane of platelets through hydrogen bonds, thereby blocking the influx of calcium and playing a role in disaggregation. This combination further drives deprotonation of more of the amino groups of the compound, and thus depolymerization can be accomplished in a shorter time without the need for elevated temperatures.
Generally, in extracorporeal blood tests, the pH proximity of the sample to be tested can vary over a wide range, as desired. However, in order to obtain a preferable depolymerization effect, the prevention and/or elimination of the pseudo-aggregation of platelets in the use of the present invention is carried out in a solution having a pH of at least 3.0, preferably at least 7.0, more preferably 7.5 to 11, and particularly preferably 9.5 to 11. The pH of the solution may be adjusted to obtain the desired depolymerization effect depending on the type of compound used and the detection requirements.
The concentration at which the compound having an amino group acts to disaggregate pseudoaggregated platelets is dependent on the number and type of amino groups contained in the compound, and also on factors such as the hydrophilicity of the compound. Generally, the concentration of the compound having an amino group for platelet depolymerization is in the range of 1 to 50mmol/L, for example: 1. 2,5, 10, 15, 20, 25, 30, 35, 40, 50 mmol/L. According to a preferred embodiment, the concentration is in the range of 2 to 20mmol/L, more preferably in the range of 5 to 15 mmol/L.
The invention provides an application of a compound with amino and salt thereof shown as a structural formula (I) in-vitro blood detection to prevent and/or eliminate false aggregation of platelets in a blood sample:
R1-NH-R2 (I)
wherein R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, SO, and R1 and R2 are not both H3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkylaryl, substituted or unsubstituted C7-14 arylalkyl, -C (O) -Q1 and-C (O) -O-Q2,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkaryl, or substituted or unsubstituted C7-14 aralkyl;
q2 is H, substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkaryl, or substituted or unsubstituted C7-14 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, halogen, -CN, -C (O) -O-P3, -O-C1-16 alkyl, -O-C6-10 aryl, -O-C7-14 alkylaryl, -O-C7-14 arylalkyl, -C (O) -C1-16 alkyl-C (O) -C6-10 aryl, -C (O) -C7-14 alkylaryl, -C (O) -C7-14 arylalkyl and-C (O) -NP1P2 wherein said-O-C1-16 alkyl, -O-C6-10 aryl, -O-C7-14 alkylaryl, -O-C7-14 arylalkyl, -C (O) -C1-16 alkyl, -C (O) -C6-10 aryl, -C (O) -C7-14 alkylaryl and-C (O) -C7-14 arylalkyl are each unsubstituted or further substituted with at least one group selected from the group consisting of-NH, -C3-C2、-OH、-SO3H. Halogen, -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of,
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-16 alkyl, C6-10 aryl, C7-14 alkaryl and C7-14 aralkyl, wherein said C1-16 alkyl, C6-10 aryl, C7-14 alkaryl and C7-14 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. Halogen, -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
According to an embodiment, wherein in the compound of formula (I), R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, -SO, provided that R1 and R2 are not both simultaneously H3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, substituted or unsubstituted C7-10 aralkyl, -C (O) -Q1 and-C (O) -O-Q2,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
q2 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, -CN, -C (O) -O-P3, -O-C1-10 alkyl, -O-C6-10 aryl, -O-C7-10 alkylaryl, -O-C7-10 arylalkyl, and-C (O) -NP1P2, wherein said-O-C1-10 alkyl, -O-C6-10 arylEach of the group consisting of, -O-C7-10 alkylaryl and-O-C7-10 arylalkyl is unsubstituted or further substituted with at least one group selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of;
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl, wherein said C1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
Preferably, in the compound of formula (I), R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, -SO, provided that R1 and R2 are not both H at the same time3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, substituted or unsubstituted C7-10 aralkyl, -C (O) -Q1 and-C (O) -O-H,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, -CN, -C (O) -O-H and-C (O) -NP1P 2;
p1 and P2 are each independently a group selected from the group consisting of: H. c1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl, wherein said C1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
Further, in the compound of the formula (I), R1 and R2 are the same or different and each independently a group selected from the group consisting of R1 and R2 is not simultaneously HH、-C(NH)-NH2Substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted phenethyl and-C (O) -Q1, wherein Q1 is as defined above.
Still further, in the compound of formula (I), Q1 is a substituted or unsubstituted C1-6 alkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted benzyl group, or a substituted or unsubstituted phenethyl group;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH and-C (O) -NP1P2,
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-6 alkyl, phenyl, benzyl, and phenethyl, wherein the C1-6 alkyl, phenyl, benzyl, and phenethyl are unsubstituted or further substituted with at least one group selected from the group consisting of-NH2、-OH、-SO3H. -COOH and-C (O) NH2Substituted with groups from the group consisting of.
The alkyl group of C1-16 can be a straight chain or branched chain alkyl group, preferably an alkyl group of C1-14, C1-12, more preferably an alkyl group of C1-10, and even more preferably an alkyl group of C1-6. Examples thereof include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-octyl, dodecyl, and hexadecyl.
The C6-10 aryl group described herein may be phenyl or naphthyl.
The C7-14 alkaryl groups described herein may be a mono-or poly-alkyl substituted aryl group. Preferably C7-10 alkaryl group such as tolyl, ethylphenyl, propylphenyl, butylphenyl, xylyl, methylethylphenyl, diethylphenyl, etc., but not limited thereto.
The C7-14 aralkyl group described herein may be a phenylalkyl group. Preferred is C7-10 aralkyl group such as benzyl, phenethyl, phenylpropyl, phenylbutyl and the like, but not limited thereto.
Substituted as described herein means substituted with at least one of the defined substituents. For the amino substituent-NP 1P2, it may be preferred according to the invention to be polyamino substituted, up to 20 amino groups. For example, 1 to 18, such as 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, etc. Preferably, the amino group is a primary amino group and/or a secondary amino group, more preferably a primary amino group. For the hydroxy substituent-OH, this is the more preferred substituent. The number of substitution of the hydroxyl groups may be 1 to 6, such as 2, 3, 4, 5, 6. Sulfonic acid groups, carboxyl groups, and nitrile groups are also preferable.
Halogen as used herein generally refers to-F, -Cl, -Br, -I, preferably-F, -Cl, -Br.
According to the following examples, the preferred amino group-containing compounds of the present invention are guanidines, alkanolamines (particularly polyhydroxyalkanolamines such as 1, 3-diamino-2-propanol), amino acids (preferably lysine, glutamine, glycine), short peptides (such as dipeptides), and polyamino-substituted multibranched or straight-chain alkanes (such as 2- (aminomethyl) propane-1, 3-diamine, 1, 3-propanediamine, etc.).
Compounds of formula (I) which may be enumerated to prevent and/or eliminate the false aggregation of platelets may be: sulfonic acids such as sulfamic acid, aminomethane sulfonic acid, taurine, sulfanilic acid, 2, 5-diaminobenzene sulfonic acid; amino acids such as glutamic acid, glutamine, arginine, lysine, alanine, glycine, N-tris (hydroxymethyl) methylglycine, 4-aminobutyric acid; short peptides, such as dipeptides, such as dilysine, dimeric glycine; alcohol/phenol amines (in particular polyhydroxyl-substituted amines), such as ethanolamine, triethanolamine, 3-amino-1-propanol, 4-amino-1-butanol, 4-hydroxybenzylamine, tyramine (4-hydroxyphenylethylamine), 1, 3-diamino-2-propanol, 3-amino-1, 2-propanediol, tris (hydroxymethyl) aminomethane, p-hydroxyphenylamine, 3, 5-dihydroxyaniline, 4-aminophenol; aromatic amines such as m-phenylenediamine and m-benzenetriamine; alkylamines, such as ethylamine, n-propylamine, n-butylamine, tert-butylamine, 1, 3-propanediamine, 2- (aminomethyl) propane-1, 3-diamine; aminonitriles, such as aminoacetonitrile, triaminopropionitrile; amides such as formamide, acetamide, carbamide, methyl asparagine, 2- (methylamino) succinamide, 2-aminoacetamide, 2-aminopropionamide, glutamine; guanidines such as guanidine, biguanide, aminoguanidine, methylguanidine, { [ amino (imino) methyl ] amine } -acetic acid, 1-acetylguanidine, and the like, but are not limited thereto.
More preferred compounds of formula (I) may be hydroxy-substituted amines, alkylamines, benzenesulfonamides, amino acids and short peptides, and guanidines.
Salts of the compounds having an amino group are also within the scope of the present invention. In particular, salts of compounds having acidic sulfonic acid groups, carboxyl groups, and the like. The salt may be a salt of an alkali metal (e.g., potassium, sodium), a salt of an alkaline earth metal (e.g., magnesium), a salt of an ammonium cation, or the like; or an inner salt. Salts of ammonium salt ions are particularly preferred.
In the detection method of the present invention in which platelet aggregation interference is excluded, a blood sample may be treated with a disaggregating agent comprising at least one of the above-mentioned compound having an amino group and a salt thereof, particularly a compound represented by formula (I) and a salt thereof. It is of course also possible to carry out the above-mentioned treatment using a depolymerization agent comprising two or more of the compounds having an amino group and salts thereof.
In the depolymerization agent of the present invention, as described above, the concentration of the compound having an amino group is in the range of about 1 to 50mmol/L, preferably 2 to 20mmol/L, and more preferably 5 to 15 mmol/L. If two or more of the compounds are used, the total concentration of each compound meets the above range. As mentioned above, the reasons for the pseudoaggregation of platelets are various, and the degree of aggregation and the degree of disaggregation are also widely varied. Therefore, the compounds having an amino group, particularly the compounds represented by the above formula (I), are used in a wide concentration range. Among them, in the case where a compound having a stronger depolymerization ability (e.g., a compound having a larger number of amino groups and/or a good cell membrane affinity) is used in a state of being easily depolymerized, a lower concentration can be used, whereas in the case where a compound having a weaker depolymerization ability is used in a state of being hardly depolymerized or having a high degree of aggregation, a higher concentration can be used. The selection of the appropriate concentration can be reasonably determined by one skilled in the art based on the following examples of the specific embodiment in combination with actual needs.
Further, according to further studies by the present inventors, it was also found that a good platelet disaggregation effect can be obtained when the blood sample is treated with a reagent containing ammonium ions. Moreover, the disaggregation of aggregated platelets by ammonium ions can also be accomplished in a short time without additional reaction conditions.
As will be seen from the following examples, various ammonium salts have substantially similar disaggregation effects on aggregated platelets at a given pH. The ammonium ion-containing compound according to the present invention may contain an anion selected from the group consisting of chloride, bromide, iodide, hydroxide, phosphate, hydrogen phosphate, dihydrogen phosphate, nitrate, hydrogen sulfide, thiocyanate, sulfate, hydrogen sulfate, sulfite, hydrogen sulfite, oxalate, carbonate, bicarbonate, formate, acetate, oxalate, propionate, malonate, citrate, and combinations thereof.
Examples of the ammonium ion-containing compound include, but are not limited to, ammonium chloride, ammonium bromide, ammonium iodide, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium nitrate, ammonium thiocyanate, ammonium bisulfite, ammonium oxalate, ammonium hydroxide, ammonium hydrogen sulfate, ammonium hydrogen carbonate, and the like.
The depolymerization agent may include one kind of compound containing ammonium ions, or may include a plurality of kinds. More preferred ammonium ion-containing compounds include ammonium chloride, ammonium bromide, ammonium phosphate, ammonium hydrogen phosphate, and the like.
When the composition further comprises an ammonium ion-containing compound, the concentration of the ammonium ion-containing compound may be in the range of 1 to 50mmol/L, such as 1,2, 5, 10, 15, 20, 25, 30, 35, 40, 50 mmol/L. The concentration of the compound containing ammonium ion is preferably 2 to 20mmol/L, more preferably 5 to 15 mmol/L.
The inventors have found that when platelet depolymerization is carried out using a compound containing ammonium ions, the pH is preferably at least 7.0, more preferably 7.5 to 11, and particularly preferably 9.5 to 11.0.
Furthermore, the present inventors have further found that when the compound having an amino group is combined with a compound containing an ammonium ion, a good depolymerization effect can be obtained at a lower concentration. That is, when the total concentration of both is comparable to the concentration when either is used alone, a better effect is obtained than when the compound containing an ammonium ion or the compound having an amino group is used alone. That is, the combination of the two has a synergistic effect on platelet disaggregation. Thus, when used in combination, the total concentration of the two may be in the range of 2 to 50mmol/L, such as 2,5, 10, 15, 20, 25, 30, 35, 40, 50 mmol/L. Preferably, the depolymerization agent may include 1 to 20mmol/L of a compound having an amino group and 1 to 20mmol/L of a compound having an ammonium ion, more preferably, the depolymerization agent may include 1 to 10mmol/L of a compound having an amino group and 1 to 10mmol/L of a compound having an ammonium ion, and even 1 to 5mmol/L of a compound having an amino group and 1 to 5mmol/L of a compound having an ammonium ion. The ratio of the both is not particularly limited. By way of example, the molar ratio of the compound having an amino group and the compound containing an ammonium ion may be in the range of 1:10 to 10:1, preferably in the range of 1:4 to 4:1 to be 1:4, 1:2, 1:1, 2:1, 4:1, and the like. Most preferably, the molar ratio of the two is 1: 1.
Without wishing to be bound by theory, the mechanism by which ammonium ions depolymerize platelets is not clear. Presumably, it is related to the concentration of ammonium ions in the solution that form hydrated ammonia. However, if aqueous ammonia is used as it is, although it has a better depolymerization performance, it is inferior to the case of using a compound containing ammonium ions, particularly ammonium salts such as ammonium chloride, ammonium phosphate and ammonium halide. Therefore, it is speculated that some kinds of anions in the solution may also play a certain role in promoting platelet depolymerization. This is different from the presumed depolymerization mechanism of the compound having an amino group.
As can be seen from the following examples, when a compound having an amino group and/or a salt thereof is used in combination with a compound having an ammonium ion, a remarkably improved depolymerization effect is obtained.
According to the present invention, the blood analyzer that performs the detection is not particularly limited. Also, the detector is not particularly limited, and a detector such as an impedance detector or an optical detector may be used.
Taking the optical detector as an example, a plurality of aggregated platelets are identified as one particle in the optical channel of the blood analyzer, and thus such aggregated platelets are larger in volume than individual platelets, stronger in fluorescence intensity than individual platelets, and fewer in number than non-aggregated platelets. As reflected in the detection information, the sample of aggregated platelets showed a large amount of platelet forward scattered light intensity information (FS) reflecting a large particle volume and a high fluorescence intensity (FL) as seen in the three-dimensional scattergram measured by the mei-rui blood cell analyzer shown in fig. 2. The volume of partially aggregated platelets reaches the volume of white blood cells, which also affects the white blood cell count. After disaggregation, platelets are in the optical channel and the particle signal recognition volume is reduced, the fluorescence intensity is reduced and the number is increased. With further reference to fig. 2, it can be seen from the three-dimensional scattergram that the platelet volume reflecting the forward scattered light (FL) of the population of disaggregated platelets is significantly reduced, the number of particles is increased, and the fluorescence intensity is reduced.
Similarly, for an impedance detector, the aggregated platelets will also be treated as a particle, producing an electrical signal. As the particle volume increases after aggregation, the volume of partially aggregated platelets reaches the volume of white blood cells, which affects the white blood cell count and changes in the histogram. This effect was evident in the early three-classification hematology analyzers.
According to the method of the present invention, by adding a disaggregating agent comprising at least one of the above-mentioned compound having an amino group and a salt thereof and a compound containing an ammonium ion to a sample, aggregation of platelets can be prevented, and already aggregated platelets can be disaggregated, whereby accurate platelet detection information can be obtained.
As used herein, "detection information" includes raw signals (e.g., electrical pulses, light intensities, etc.), information obtained by processing, such as histograms, scatter plots, etc., and finally reported classification and/or count information.
The disaggregating agent of the present invention is effective for platelet aggregation caused by various causes, and thus is not particularly limited to blood samples. The sample may be from peripheral blood, such as from peripheral blood or venous blood. The sample can be obtained by any method, such as pricking with a sharp needle or taking blood from an anticoagulation vessel. Freshly collected blood may be used in anticoagulation tubes coated with conventional anticoagulants such as EDTA, as the composition of the invention also has a very good effect on the pseudoaggregation of platelets due to EDTA induction.
Generally, the blood sample may be subjected to any conventional treatment to obtain a test sample. The processing may be, for example: diluting, dyeing, and cracking. In the method of the invention, the disaggregating agent may be added to the sample as a separate treatment agent (e.g., as a platelet disaggregating agent) or may be added to the sample with the treatment agent at any one of the steps of treating the sample. Thus, the depolymerizing agent of the present invention can be formed as a single treatment agent; it is also possible to form a diluent, a staining agent or a lysing agent having a platelet disaggregation effect by including at least one of the compound having an amino group and a salt thereof, and/or a compound containing an ammonium ion in a reagent for dilution, staining or lysing treatment, thereby simultaneously exerting an effect of preventing/eliminating platelet disaggregation in any one step of the treatment without hindering the treatment.
The reaction to disaggregate platelets in the methods of the invention does not require additional incubation (e.g., low temperature or heat). The sample can be detected by mixing the disaggregation agent and the sample uniformly and then depolymerizing the platelets within about 30 seconds.
According to the invention, the sample may be from a mammal, preferably a primate, more preferably a human.
More specifically, the detection method of the present invention may comprise subjecting a blood sample to a treatment for preventing and/or eliminating platelet aggregation in the blood sample with a disaggregating agent comprising at least one compound selected from a compound having an amino group and optionally a compound containing an ammonium ion, and detecting the blood sample treated with the disaggregating agent with a blood analyzer to obtain at least detection information of leukocytes.
The detection information may be a pulse signal for the particles in the sample or an optical signal, depending on the detector used. The blood analyzer may process the detection information to further obtain detection parameters of the blood cells such as histogram, scatter plot, classification and/or counting.
According to one embodiment, the blood analyzer comprises an impedance detector, the blood sample may be further hemolyzed with a red blood cell lysing agent in addition to being treated with a disaggregating agent before the detection, and the method comprises the steps of: and detecting the blood sample treated by the depolymerizing agent and the red blood cell cracking agent by using an impedance detector in a blood analyzer to obtain electric signals of particles in the blood sample and further obtain white blood cell detection parameters.
Three classifications and counts of white blood cells are obtained by the impedance detector.
According to yet another embodiment, the blood analyzer comprises an optical detector, the blood sample is further stained with a fluorescent dye and hemolyzed with a red blood cell lysing agent, and the method comprises: and detecting the blood sample treated by the depolymerizing agent, the fluorescent dye and the red blood cell cracking agent by using an optical detector in a blood analyzer to obtain at least two optical signals of particles in the blood sample so as to obtain the detection information of the white blood cells.
Preferably, in this embodiment, the at least two light signals are selected from the group consisting of a fluorescence intensity signal, a forward scattered light intensity signal, and a side scattered light intensity signal.
In leukocyte assays, four classifications (i.e., eosinophils, neutrophils, monocytes, and lymphocytes) can be obtained, for example, using the DIFF assay channel of a Meyer's blood monitor, or basophil assay information can be further obtained using the WNB channel as in a Meyer's blood monitor. "
In the above detection method, the disaggregating agent, the fluorescent dye, and the erythrocyte lysis agent may be used as separate reagents or may be combined into a mixed reagent. For example, the disaggregating agent may be formed as a diluent, a staining agent, a lysing agent, a stain-lysing agent, or the like having a platelet disaggregating effect.
Therefore, the invention also provides a reagent for detecting the leucocyte in the extracorporeal blood detection.
Since the volume of the reagent used for processing the blood sample is much larger than the volume of the blood sample in the extracorporeal blood test, the processing conditions such as concentration, pH and the like in the above-mentioned applications are generally equally applicable to the reagent for resisting platelet aggregation interference of the present invention.
According to the present invention, the reagent may include at least one selected from the group consisting of a compound having an amino group and a salt thereof and a compound containing an ammonium ion, a buffer and an osmotic pressure regulator, and optionally a fluorescent dye and/or a surfactant, wherein the concentration of the compound having an amino group is 1 to 50mmol/L, and the concentration of the compound containing an ammonium ion is 1 to 50 mmol/L. The concentration defined in the present invention is the total concentration of two or more compounds having an amino group. Likewise, the concentration is also the total concentration for two or more ammonium ion containing compounds. The at least one compound having an amino group is as defined above and will not be described herein again. The concentration is preferably 2 to 20mmol/L, more preferably 5 to 10 mmol/L.
The further at least one compound containing ammonium ions is also as defined above, and its concentration is preferably 2 to 20mmol/L, more preferably 5 to 10 mmol/L. According to a preferred embodiment, when the reagent contains both a compound having an amino group and a compound containing an ammonium ion, the concentration of both can vary from 1 to 20mmol/L, from 1 to 10mmol/L, or even from 1 to 5 mmol/L. The molar ratio of the two may be any ratio, and may vary, for example, in the range of 1:10 to 10:1, preferably 1:4 to 4:1, of the compound having an amino group to the compound having an ammonium ion.
The pH of the reagent is not particularly limited in relation to its reagent use requirements. Preferably, the pH of the reagent is at least 3.0, at least 7.0, preferably 7.5 to 11, particularly preferably 9.5 to 11. The pH of the reagent may be adjusted by conventional buffering agents. The present invention is not particularly limited with respect to the kind of the buffer used for the reagent. For example, a citric acid buffer pair, a phosphoric acid buffer pair, a boric acid buffer pair, a phthalate buffer pair, a 3- (N-morpholine) ethanesulfonic acid buffer pair, a 4-hydroxyethylpiperazine ethanesulfonic acid buffer pair, and the like can be used, but are not limited thereto.
The reagent should have a certain osmotic pressure. The osmotic pressure can vary according to the actual requirements of the reagent, for example, for a diluent, 200mOsm/L can be preferred within the range of 180-240 mOsm/L; for example, the amount of the cracking agent is 70-130 mOsm/L, preferably 90 mOsm/L. The agent may include an osmotic pressure regulator. The agent of the present invention is not particularly limited as to the osmotic pressure adjusting agent, and may be, for example, inorganic salts such as sodium chloride, potassium chloride and the like; saccharides such as glucose, mannose, fructose, maltose, etc., but not limited thereto.
The reagent may also include a surfactant. The reagent may include surfactants of different functions depending on the purpose of detection. For example, in the case of leukocyte assays, the reagents may include a surfactant that alters the permeability of the cell membrane to facilitate the passage of nucleic acid dyes across the cell membrane into the interior of the cell for binding to nucleic acids. Such surfactants are for example: phenoxyethanol, sodium dioctadecylamine, sodium N-methylaminocarboxylate, and the like, but are not limited thereto.
In addition, the agent may further include other necessary components such as a preservative, an antibacterial agent, a cell membrane protective agent, a chelating agent, and the like, as necessary. The addition can be selected as desired by one skilled in the art.
According to one embodiment of the invention, the reagent may act as a diluent for the blood sample. For example, the diluent may be a diluent for impedance detection or a diluent for optical detection. Formulations of diluents which may be mentioned are, for example:
according to the invention, the reagent may also be a staining agent. Generally, in platelet testing machines, dyes are stored separately in the form of organic solutions, since they are mostly soluble in organic solvents. If necessary, a dye may be added to the above diluent to prepare a coloring agent. The dye in the stain may be a nucleic acid dye. Examples of the nucleic acid-specific dye include, but are not limited TO, asymmetric cyanine dyes, thiazole orange TO dyes, oxazole orange YO dyes, acridine orange AO dyes, and specific examples thereof include PI, DAPI, and Hoechst series (e.g., Hoechst33258, Hoechst 33342). More preferred nucleic acid dyes are asymmetric cyanine dyes, such as SYBR Green, for example. The pH value of the dye for optimal dyeing is approximately consistent with the pH value of the compound with amino and the compound containing ammonium ions for optimal effect. The stain may also be a mitochondrial stain (e.g., Janus Green B, MitoLite Red, rhodamine 123, Mitotracker Green, Mitotracker Deep Red, Mitotracker Red, etc.) or a membrane stain (e.g., DiA, DiD, DiI, DiO, DiR, DiS, FDA, Alexa Fluor 488, Super Fluor 488, etc.) depending on the detection requirements.
Such a stain formulation may be:
in addition, the reagent of the present invention may be a lytic reagent, and may be used in the detection of leukocytes. The lysing agent used in the reagent may be any conventional red blood cell lysing agent. As mentioned above, the compounds having an amino group, particularly the compounds containing an ammonium ion, in the reagent of the present invention do not adversely affect erythrocytes in a defined concentration range, and therefore the kind and concentration of the lytic agent in the reagent, and the manner of use are the same as those in the prior art. Examples of the erythrocyte lysis reagent include quaternary ammonium salts (e.g., dimethylbenzyl ammonium chloride, dodecyltrimethylammonium chloride, dimethylbenzylalkylammonium chloride, etc.), but are not limited thereto. Such a lysing agent formulation may be:
again, according to the foregoing, the reagent of the present invention comprising a compound having an amino group and a compound containing an ammonium ion is capable of preventing/eliminating false aggregation of platelets, has a low concentration of an active ingredient, does not require additional reaction conditions (such as cooling or heating), does not require a prolonged reaction time, and can complete depolymerization of platelets within 30 seconds, so that the compound does not adversely affect the detection of blood, does not affect the detection steps and conditions, and can eliminate interference with platelet aggregation under existing equipment and detection methods.
Examples
Example 1 comparison of the ability of Compounds with and without amino groups of similar Structure to disaggregate platelets
This example compares the effect of amino group-containing and non-amino group-containing compounds having similar structures and substituents on platelet disaggregation. The compounds tested are shown in table 1 below:
table 1: test Compounds having amino group and Compounds having similar Structure and having no amino group
The compounds in Table 1 above were added to dilutions used in a hemocytometer to prepare dilutions of blood samples. A blood sample of platelet aggregation was obtained by treating the blood sample with a final concentration of 0.01mmol/L of platelet aggregation-inducing agent ADP. The diluent consists of: citric acid (0.5g/L), surfactant phenoxyethanol (0.1g/L), bacteriostatic agent (6g/L), sodium chloride (3g/L) and EDTA (0.1 g/L). The compounds shown in Table 1 (final concentration: 0.01mol/L) were added to each of the dilutions, and the treatment solutions were obtained by adjusting the pH of the dilutions to 14 and the osmotic pressure to 200 mOsm/L.
Venous blood from healthy subjects was collected into a blood anticoagulation tube for use. Two 1ml portions of blood were taken, one portion was added to the above diluent, and after mixing well, platelet counts were determined in a blood cell analyzer (mai ri BC-6000Plus) and recorded as: PLT _ O (unpolymerized); the other part was added with platelet aggregation inducer ADP (final concentration 0.01mmol/L) and mixed well. Platelet aggregation occurred after 5 minutes, at which time platelet counts were obtained by adding the above diluent and then examining the blood containing aggregated platelets with the hematology analyzer and are reported as: PLT _ O (not depolymerized). Adding a platelet aggregation inducer ADP (final concentration is 0.01mmol/L) into another 1ml of blood, uniformly mixing, adding the treatment solution after 5 minutes, uniformly mixing, and detecting the count of the platelets in the treated blood by using the blood cell analyzer, wherein the count is recorded as: PLT _ O (disaggregation).
Generally, PLT _ O (not depolymerized) < PLT _ O (unpolymerized).
The term "depolymerization rate" referred to herein is calculated by the following formula:
depolymerized samples: depolymerization rate PLT _ O (depolymerized)/PLT _ O (unpolymerized); or
Non-depolymerized (control) samples: the depolymerization rate was PLT _ O (not depolymerized)/PLT _ O (not polymerized).
The treatment solutions containing the compounds of Table 1 were tested one by one for the rate of platelet depolymerization after ADP-induced blood treatment as described above and shown in Table 2 below.
TABLE 2 disaggregation effect of Compounds having amino group and structurally similar Compounds not having amino group on platelets
As can be seen from table 2 above, the compound containing only amino groups disaggregates already aggregated platelets, while other groups such as sulfonic acid groups, hydroxyl groups, carboxyl groups, carbonyl groups, etc., hardly disaggregate aggregated platelets (comparable to the disaggregation ratio of NaCl blank control). From this example it can be determined that the amino group of each compound that is responsible for the main disaggregation of platelets.
Example 2 correlation of the number of amino groups with the ability of platelets to disaggregate
This example compares the effect of varying amino numbers on platelet disaggregation on structurally similar compounds. The compounds having different numbers of amino groups were tested in the same manner as in example 1, and the platelet aggregation rates and pKa values obtained for each compound are shown in Table 3.
TABLE 3 platelet disaggregation ratios and pKa values for compounds containing varying numbers of amino groups
As can be seen from table 3 above, the disaggregation effect of the compound on aggregated platelets increases with the increase in the number of amino groups, with short peptides, polyamino-substituted alkylamines, polyamino-substituted hydroxylamines and guanidines being more preferred, having similar or identical structures, and differing numbers of substituted amino groups only.
Example 3 relationship between amino group pka and platelet aggregation ability under the same pH Environment
This example compares the effect of different amine pKa of structurally similar compounds on platelet disaggregation at the same pH. According to substantially the same manner as in example 1 except that different types of compounds were adjusted to more suitable pH values, compounds having different numbers of amino groups were tested separately, and the platelet aggregation ratios and pKa values of the respective compounds were obtained as shown in Table 4.
TABLE 4 platelet disaggregation rates for compounds with different amino pKa at a certain environmental pH
As can be seen from Table 4 above, the different pKa values of the amino groups are affected by the different substituents on the amino groups.
Example 4 relationship of environmental pH and amino pKa of Compounds having an amino group and its Effect on depolymerization Capacity
From example 3 it can be seen that there is a relationship between the ambient pH and the pKa of the amino group of the compound with the amino group. In order to further study the relationship between the environmental pH and the amino pKa of the amino compound and the influence on the platelet depolymerization ability, 1-acetylguanidine, a compound with a pKa of 8.33, was selected in this example, and a set of tests was performed in a manner similar to that of example 1, with only the environmental pH being changed between 7.0 and 10. A graph of pH versus depolymerization rate was obtained, as shown in FIG. 3.
As can be seen from fig. 3, the pH of the environment has a strong correlation with the pka of the substance in platelet disaggregation. When the pH was increased, the depolymerization ability of the amino group-containing substance was increased, and the depolymerization rate was increased from 35.23% to 97.32%. When the pH value is more than 9.5, the depolymerization rate is almost constant. It can be seen that when the ambient pH is to some extent greater than the amine pKa of the compound, continued increase in pH has little effect on the depolymerization effect. This is consistent with the previously postulated depolymerization mechanism. That is, at a suitable pH, the amino groups of the compounds are present in solution in largely deprotonated form, thereby facilitating or even accelerating the depolymerization.
Further, in a similar manner, at ph9.5, the disaggregation ratio of aggregated platelets by compounds having different amine pKa was examined, and the results are shown (fig. 4). Wherein, some compounds with pKa values between 8 and 11 are selected: n- (trihydroxymethyl) methylglycine (8.1), arginine (9.0), glutamic acid (9.6), glycine (9.6), sulfanilic acid (10.1) and lysine (10.7). As the amino group pKa8.1 was increased to 10.7, the depolymerization effect of each compound tended to be decreased.
As can be seen from this example, adjusting the pH to a value higher than the pKa of the amino group contributes to an improvement in the depolymerization effect. Therefore, the ability of the compound having an amino group to disaggregate aggregated platelets can be improved by adjusting the pH of the environment. Conversely, a suitable compound having an amino group can be selected according to the requirements of the detection environment.
Example 5 disaggregation Effect of Compound Structure having amino group on aggregated platelets
In order to examine the influence of the structure of the compound on the depolymerization of aggregated platelets, compounds having representative structures were selected and tested according to the method of example 1, all at pH9.5, to obtain the depolymerization rates of the respective compounds, as shown in table 5 below.
TABLE 5 disaggregation Effect of different Compounds on aggregated platelets
As is apparent from Table 5 above, the interaction of amino groups with cell membranes is influenced by the structure of the substance itself having amino groups. For example, dimeric glycine has the same pKa as glycine and has one more secondary amino group, but the depolymerization effect is still slightly lower than glycine. This is attributable to one more carbonyl group in the molecule. In addition, both glutamic acid and glycine have only one primary amino group with pKa of 9.6, but glutamic acid has one more carboxyl group than glycine, and the depolymerization rate is also low.
As can be seen from table 5, the carbonyl and carboxyl groups seem to be of no help to enhance the platelet disaggregation effect of the compound, while the alkyl chain has little effect on the disaggregation effect.
In addition, the higher the number of amino/imino groups, particularly primary amino groups, the better the depolymerization effect. Arginine has more amino/imino groups, but the depolymerization effect is not very good, possibly related to its ability to form cyclic lactams, resulting in impaired amino groups.
In addition, the hydroxyl group seems to be more advantageous in enhancing the depolymerization effect of the amino group in the compound. For example, aminomethane tris (hydroxymethyl) acetate contains only one secondary amino group, but the depolymerization rate is still higher than glycine. Trimethylolaminomethane having primary amino group has a more excellent effect of disaggregating platelets. It is speculated that the hydroxyl groups favor the compound towards the cell membrane of the platelets, whereas primary amino groups have a superior disaggregating effect on platelets than secondary amino groups. Of course, a higher rate of depolymerization also correlates with a lower pKa (8.1) for both compounds.
In addition, tertiary amino groups have little depolymerization effect. As is clear from the above mechanism, the amino group is difficult to function without hydrogen atoms capable of forming hydrogen bonds.
Example 6 disaggregation Effect of Compounds with amino groups on different models of platelet aggregation
Platelet aggregation can be induced by a variety of substances, which in turn lead to blood clotting. In order to examine the disaggregation effect of the compound having an amino group on platelet aggregation induced by various factors, this example established various models of platelet aggregation including Adenosine Diphosphate (ADP), Thrombin (THR), Collagen (COL) and Ristocetin (RIS) by selecting a platelet aggregation-inducing substance in a blood coagulation assay protocol based on the existing platelet aggregation pathway. It was found by this example that ADP, THR, COL, and RIS induce aggregation of platelets to different degrees with changes in concentration and time, and that the compound having an amino group can also effectively disaggregate platelets to different causes and aggregation degrees within a certain concentration and time range.
See fig. 5, which shows the extent of platelet aggregation induced with different concentrations of ADP (0.01-1 mM) versus time. Specifically, 1ml of venous blood was taken, respectively, and ADP was added to give final concentrations of 0.01mM, 0.25mM, 0.5mM and 1mM, respectively. Blood containing aggregated platelets was examined with a hematology analyzer. The blood cell analyzer obtains the characteristics of various cell particles in blood through the impedance channel and the optical channel, including the quantity, the size and the like. After normal blood is collected into a blood anticoagulation tube, the platelet number detected by the impedance channel is obtained by a blood cell analyzer and is recorded as (PLT _ I). When platelet aggregation occurs, the volume of aggregated platelets is much greater than the volume of a single platelet and therefore cannot be correctly counted by the platelet-corresponding recognition mechanism, resulting in a drop in platelet count, denoted PLT _ I (aggregation). The compound containing amino groups is not added into the diluent of the impedance channel, so that the impedance channel reflects the degree of platelet aggregation in an aggregation model. The count before platelet aggregation was PLT _ I (no aggregation), the count after platelet aggregation was PLT _ I (aggregation), and the aggregation rate was PLT _ I (aggregation)/PLT _ I (no aggregation). The number of platelet particles detected by the optical channel was obtained by the hematology analyzer and reported as (PLT _ O). When platelet aggregation occurs, the volume of aggregated platelets is much greater than the volume of a single platelet and therefore cannot be correctly counted by the platelet-corresponding recognition mechanism, resulting in a drop in PLT _ O (not disaggregated). Disaggregation of aggregated platelets was achieved using compounds containing such amino groups in dilutions of optical channels to obtain disaggregated PLT _ O (not disaggregated). The count before platelet aggregation was PLT _ O (not aggregated) and the count after platelet aggregation was PLT _ O (not disaggregated). Generally, PLT _ O (not depolymerized) < PLT _ O (unpolymerized), and the depolymerization rate is PLT _ O (depolymerized)/PLT _ O (unpolymerized). Through the principle, a model is established, and the depolymerization effect of the compound containing the amino group is quantitatively detected.
As can be seen from fig. 5, the aggregation of platelets reached a substantial maximum within 5 minutes after the addition of ADP. And the larger the amount of ADP added, the higher the degree of aggregation of platelets. The degree of platelet aggregation is influenced approximately the same for ADP final concentrations above 0.25 mM. In addition, ADP at a concentration of 0.01mM has the least effect on the extent of platelet aggregation, allowing up to about 35% of platelets to aggregate, but at this concentration the platelets disaggregate relatively slowly.
With further reference to figure 6, there is shown the time course of the effect of a compound having an amino group on platelet disaggregation for blood samples induced with different ADP concentrations. Specifically, each blood sample to which different concentrations of aggregation-inducing agent were added was subjected to a post-treatment measurement in a similar manner to example 1 by adding a compound having an amino group (1-acetylguanidine) to the diluted solution, and the measurement was carried out once at an interval of 5 minutes after each sample was added to the treatment solution, to obtain the change in depolymerization rate with time. The composition of the diluent was: citric acid (0.5g/L), surfactant phenoxyethanol (0.1g/L), bacteriostatic agent (6g/L), sodium chloride (3g/L), EDTA (0.1g/L) and 1-acetylguanidine (10mmol/L), pH is 9.5, and osmotic pressure is 200 mOsm/L.
As can be seen from fig. 6, the same compound showed significant disaggregation effects at the same concentration for different degrees of platelet aggregation, and the disaggregation effect reached the highest immediately after the addition of the compound having an amino group and decreased with time, but became stable substantially after 10 minutes. In addition, the effect is more stable as the concentration of ADP is lower. Considering that the blood cell measuring apparatus can complete the measurement of the sample rapidly with only a small amount of the sample, the measurement can be started within 5 minutes, preferably within 2 minutes, and more preferably within 30 seconds after the treatment liquid containing the compound having an amino group is added.
Thus, by increasing the concentration of ADP, the degree of aggregation can be increased, thereby increasing the difficulty of depolymerization.
Similarly, fig. 7 and 8 are graphs of the induced platelet aggregation test with different concentrations of THR. Essentially the same procedure as described above is followed except that ADP is replaced by THR. Wherein the concentration of THR is 0.1U, 0.15U, 0.2U, 0.23U, 0.25U, 0.28U, 0.30U and 0.35U, respectively. It can be seen that the effect of aggregating platelets was weak at low concentrations of THR, and that the rate of platelet aggregation rapidly increased after 1 minute at high concentrations. This is because, after a certain concentration of THR is added, soluble fibrinogen is converted into insoluble fibrinogen, which causes blood coagulation, and platelets are also wrapped by the insoluble fibrinogen, resulting in a sharp increase in aggregation rate. At the same time, the depolymerization effect of 1-acetylguanidine reached the highest immediately for each THR concentration, but began to decrease significantly after 1 minute. In this case, the depolymerization agent does not exhibit its effect. But better rates of disaggregation were obtained in samples tested immediately after treatment.
Fig. 9 and 10 are graphs of the platelet aggregation induction assay with different concentrations of COL. Basically the same procedure as described above is followed except that ADP is exchanged for COL. Wherein the concentration of COL is 0.05mM, 0.1mM, 0.5mM, 1mM, 5mM, 10mM and 20mM, respectively. It can be seen that COL rapidly aggregated platelets to nearly 100% at different concentrations, with the lower the concentration, the faster the aggregation. Meanwhile, the depolymerization effect of 1-acetylguanidine reaches the highest concentration immediately for each other COL except for the sample with the lowest COL concentration, but starts to be obviously reduced after about 4-8 minutes. This is also due to the conversion of soluble fibrinogen to insoluble fibrinogen upon addition of COL, resulting in blood clotting.
Fig. 11 and 12 are graphs of platelet aggregation-induced tests with different concentrations of RIS. Basically the same procedure as described above is used, except that ADP is replaced by RIS. Wherein the concentration of RIS is 0.15mM, 0.375mM, 0.75mM, 1.5mM and 3mM, respectively. It can be seen that the induction of platelet aggregation by RIS takes a long time to develop, and after 15-20 minutes, the degree of platelet aggregation begins to reach the maximum. Meanwhile, the depolymerization effect of the 1-acetylguanidine can reach the highest immediately for each RIS concentration and is relatively stable within 10 minutes. The rapid decrease in the rate of disaggregation after 15 minutes is also due to the clotting of the blood in the sample.
From the above models for inducing platelet aggregation, it can be seen that aggregation inducers under different pathways have different effects on the degree of platelet aggregation, but the aggregation of compounds with amino groups to each inducers can be immediately effective, but the soluble fibrinogen is converted into insoluble fibrinogen to cause coagulation, so that the disaggregation effect after the coagulation of the samples in which THR and COL induce platelet aggregation is not shown. This has little effect on platelet sorting and counting by the blood cell analyzer.
This indicates that the compound having an amino group can produce a good depolymerization effect in a range of concentrations and time for a variety of platelet aggregation conditions, and all have a rapid onset of action, facilitating immediate detection without additional reaction conditions (e.g., heating or long reaction time).
Example 7 disaggregation of aggregated platelets with Compounds containing ammonium ions
This example measures the effect of compounds containing ammonium cations on disaggregation of aggregated platelets.
The test was carried out in the same manner as in example 1 except that the compounds in Table 1 were replaced with compounds containing ammonium ions (ammonium chloride, ammonium bromide, ammonium iodide, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium thiocyanate, ammonium hydrogen carbonate, ammonium oxalate, aqueous ammonia) and a control compound (NaCl), and the pH of the treatment solution was adjusted to 9.5 and the osmotic pressure was adjusted to 200 mOsm/L. The measured depolymerization rates of the ammonium ion compounds at different concentrations are shown in fig. 13.
As can be seen from FIG. 13, in the sample in which platelet aggregation was induced with 0.01mmol/L ADP, each of the compounds containing ammonium ions produced some depolymerization at a concentration of 1mmol/L and reached the best effect at a concentration of 10 mmol/L. Specifically, at 10mmol/L, (NH)4)2HPO499.25% NH4CL is 95.70%, (NH)4)3PO494.87% NH4Br of 93.48%, NH4I of 92.75%, NH4HCO388.68% NH4C2O487.67% NH4H2PO486.24% NH4SCN 85.78%, NH4OH was 83.05%. When the ammonium ion compound was replaced with NaCl, the depolymerization effect decreased to 18.90%. It can be seen that ammonium ions, rather than anions, act to disaggregate platelets. Also different anions have some, but not much, influence on depolymerization.
Example 8 Effect of ambient pH on platelet disaggregation Capacity of Compounds containing ammonium ions
This example investigates the effect of ambient pH on the disaggregation effect of compounds containing ammonium ions on aggregated platelets. The depolymerization rate of ammonium chloride to platelets in the sample was measured in a similar manner to example 1 by replacing the compounds in Table 1 with 0.01mol/L ammonium chloride and adjusting the pH of the treatment solution to 4.0, 5.5, 6.5, 7.5, 8.5, 9.5 and 11.0, respectively, as shown in Table 6 below.
Table 6: effect of pH on ammonium ion depolymerization of platelets in ammonium chloride
pH value | 4.0 | 5.5 | 6.5 | 7.5 | 8.5 | 9.5 | 11.0 |
Rate of depolymerization | 18.62% | 31.70% | 59.61% | 94.05% | 94.62% | 95.70% | 97.72% |
As can be seen from Table 6, at an ambient pH of 7.5 or more, the disaggregation of aggregated platelets by ammonium ions suddenly increased to 94.05%, and was maintained at a high disaggregation rate in the pH range of 7.5 to 11.0. This suggests that the depolymerization of platelets is promoted when ammonium ions form a large amount of ammonium hydrate in the solution.
Example 9 Effect of Compounds having amino groups in combination with Compounds containing ammonium ions on platelet depolymerization
This example determined the effect of a combination of a compound having an amino group and a compound containing an ammonium ion on platelet disaggregation, based on the possibility that the compound having an amino group and the compound containing an ammonium ion disaggregate aggregated platelets by different disaggregation mechanisms. Following a procedure similar to example 1, except substituting the compounds of Table 1 with ammonium chloride, 1-acetylguanidine, a combination of ammonium chloride and 1-acetylguanidine at concentrations of 1,2, 5, 10, 20 and 50mmol/L, respectively, and NaCl as a control, wherein the concentrations of ammonium chloride and 1-acetylguanidine in the combination of ammonium chloride and 1-acetylguanidine were equal and the total concentration met the above concentration requirements. In addition, in order to highlight the effect of the combination of both, in this example, 0.1mmol/L of ADP (i.e., 10 times the concentration of ADP in example 1) was used to induce platelet aggregation, and the ability of a compound having an amino group and a compound having an ammonium ion to disaggregate platelets was investigated while increasing the degree of difficulty in disaggregation. The measured depolymerization rates are shown in FIG. 14.
The results show (FIG. 14) that in the ADP-induced platelet aggregation at a final concentration of 0.1mmol/L, NH was present as the concentration increased4The depolymerization effects of Cl and 1-acetylguanidine were gradually increased, respectively. For example, 50mmol/L NH alone4The Cl depolymerization effect was 66.27%, the single 50mmol/L depolymerization effect of 1-acetylguanidine was 62.14%, NH4The combined action of Cl and 1-acetylguanidine at the total concentration of 50mmol/L enables the depolymerization effect to reach 95.48 percent, and the effect of further enhancing the platelet depolymerization is achieved. This enhanced effect is also seen at other concentrations. Suggesting synergy between the two in platelet aggregation. Therefore, the combination of the two is preferably used at a lower concentration (e.g., as low as 1-20 mM, 1-10 mM, or even 1-5 mM, respectively).
The following further experiments were conducted on the use of the reagent comprising a compound having an amino group of the present invention for interference of antiplatelet depolymerization in actual tests.
Test example 1 Compound having amino group for leukocyte detection in lysate
This test example provides a lysate used for a blood cell analyzer, which can be used for detecting white blood cells disaggregated by platelets. The test example and the following test examples were measured by using a blood cell analyzer (BC-6000Plus) of Shenzhen Merrill biomedical corporation, Inc., and lysates were prepared according to the following formula:
control lysate:
lysis solution B:
1-Acetylguanidine was added to a final concentration of 0.01mol/L based on the control lysate.
The control lysate and lysate B were prepared with distilled water at 25 ℃ with pH adjusted to 9 and osmotic pressure of 90 mOsm/L.
Taking 1ml of a human venous blood sample collected in an anticoagulation tube, dividing the sample into two groups, and performing measurement with the blood cell analyzer, wherein a control lysate and a lysate B are used, respectively, 20. mu.l of the sample is mixed with 1ml of the lysate, 20. mu.l of a DNA stain (Hoechst33342) is further added, the temperature can be maintained at about 42 ℃, fluorescence intensity information (FL) of the blood sample cells after the treatment is measured by lateral fluorescence at a measurement angle of 90 °, lateral scattered light intensity information (SS) of the blood sample cells after the treatment is measured by lateral scattered light at a measurement angle of 90 °, and forward scattered light intensity information (FS) of the blood sample cells after the treatment is measured by forward scattered light at a measurement angle of 2 ° to 5 °. Another 1ml of the blood sample is added with platelet aggregation inducer ADP (final concentration is 0.01mmol/L) and mixed evenly. The platelets formed aggregates after 5 min. At this time, the samples were divided into two groups, which were also detected by a hematology analyzer, treated with control lysate and lysate A, respectively, and added with DNA dye, and a three-dimensional scattergram was similarly obtained. The 4 scattergrams obtained by the sample measurement are shown in FIG. 15.
In the optical channel, a plurality of aggregated platelets are recognized as one particle, and the volume of the partially aggregated platelets reaches the volume of white blood cells, affecting the detection of the count of white blood cells. In this test exampleIn (1), the leukocyte count of the unaggregated sample was determined to be 7.39X 109In which neutrophils were classified and counted 4.09X 109Lymphocyte 2.35X 109Monocyte 0.32X 109Eosinophils 0.52X 109. The white blood cell count after depolymerization, determined using the sample of lysate B, was 7.42X 109Differential counting of neutrophils 4.13X 109Lymphocyte 2.31X 109Monocyte 0.34X 109Eosinophils 0.58X 109. Measurement of the white blood cell count after aggregation 8.02X 10 Using samples of control lysates9Differential counting of neutrophils 4.37X 109Lymphocyte 2.56X 109Monocyte 0.41X 109Eosinophils 0.63X 109. Therefore, the counting and classification of the white blood cells are not influenced by the aggregation of the platelets after the lysate B is used, and the counting is more accurate.
Test example 2: method for detecting leucocyte by using ammonium chloride in lysate
The present test example provides a lysate used for a blood cell analyzer, which can be used to eliminate platelet aggregation interfering with the detection of leukocytes. The lysate was prepared according to the following formula:
control lysate:
lysate a:
ammonium chloride was added to a final concentration of 0.01mol/L based on the control lysate.
Control lysate and lysate A were prepared with distilled water at 25 ℃ with pH adjusted to 9 and osmotic pressure of 90 mOsm/L.
According to a procedure similar to that of test example 1, 1ml of a human venous blood sample collected in an anticoagulation tube was taken, the sample was divided into two groups, and measurement was performed by the blood cell analyzer, wherein a control lysate and a lysate A were used, respectively, 20. mu.l of the sample was mixed in a ratio of 1ml of the lysate to 20. mu.l of the sample, 20. mu.l of a DNA stain (Hoechst33342) was further added, the temperature was maintained at about 42 ℃, fluorescence intensity information (FL) of the blood sample cells after the treatment was measured using a side fluorescence at a measurement angle of 90 °, side scattered light intensity information (SS) of the blood sample cells after the treatment was measured using a side scattered light at a measurement angle of 90 °, and forward scattered light intensity information (FS) of the blood sample cells after the treatment was measured using a forward scattered light at a measurement angle of 2 ° to 5 °. Another 1ml of the blood sample is added with platelet aggregation inducer ADP (final concentration is 0.01mmol/L) and mixed evenly. The platelets formed aggregates after 5 min. At this time, the samples were divided into two groups, which were also detected by a hematology analyzer, treated with control lysate and lysate A, respectively, and added with DNA dye, and a three-dimensional scattergram was similarly obtained. The 4 scattergrams obtained by the sample measurement are shown in FIG. 16.
In the optical channel, a plurality of aggregated platelets are identified as one particle, and the volume of partially aggregated platelets reaches the volume of white blood cells, affecting the white blood cell count. Detection of (3). In this test example, the leukocyte count in the unaggregated sample was determined to be 7.49X 109Wherein the neutrophil is 4.74X 109Lymphocyte 2.16X 109Monocyte 0.42X 109Eosinophils 0.14X 109. The white blood cell count after disaggregation was 8.72X 10 as determined using a sample of control lysate9Differential counting of neutrophils 5.16X 109Lymphocyte 2.57X 109Monocyte 0.61X 109Eosinophils 0.32X 109. The number of white blood cell counts after depolymerization, measured using a sample of lytic agent A, was 7.58X 109Wherein the neutrophil is 4.79X 109Lymphocyte 2.21X 109Monocyte 0.39X 109Eosinophils 0.15X 109. It can be seen that the white blood cell count and classification was not affected by platelet aggregation after lysis agent a was used, and the count was more accurate.
Test example 3: combination of compounds having amino groups and compounds containing ammonium ions for leukocyte detection in lysates
This test example was conducted in accordance with the procedure of test example 5 except that lysate C was prepared instead of lysate CFor lysate B, i.e.on the basis of the control lysate, equimolar amounts of 1-acetylguanidine + NH are added4Cl was brought to a final concentration of 0.01 mol/L.
Control lysate and lysate C were prepared with distilled water at 25 ℃ with pH adjusted to 9 and osmotic pressure of 90 mOsm/L.
The test was carried out in a similar manner to test example 5, and a three-dimensional scattergram was similarly obtained as shown in FIG. 17.
In this test example, the unaggregated sample was measured to have a measured white blood cell count of 6.19X 109In which neutrophils were classified and counted at 3.87X 109Lymphocyte 1.91X 109Monocyte 0.22X 109Eosinophils 0.08X 109. Measurement of white blood cell count after depolymerization with a sample of lysate C was 6.13X 109Differential count of neutrophils 3.91X 109Lymphocyte 1.88X 109Monocyte 0.21X 109Eosinophils 0.07X 109. The white blood cell count after disaggregation was 6.97X 10 determined using a sample of control lysate9Differential counting of neutrophils 4.21X 109Lymphocyte 2.21X 109Monocyte 0.34X 109Eosinophils 0.17X 109. Therefore, the counting and classification of the white blood cells are not influenced by the aggregation of the platelets after the lytic agent C is used, and the counting is more accurate.
Test example 4: disaggregation effect of compound having amino group on pseudo-platelet aggregation in clinic
The test example was to achieve disaggregation of pseudoaggregated platelets in the clinic. The same dilution as dilution B of test example 1 was used for the detection. The formula of the diluent is as follows: citric acid (0.5g/L), surfactant phenoxyethanol (0.1g/L), bacteriostatic agent (6g/L), sodium chloride (3g/L) and 1-acetyl guanidine (10 mmol/L). The pH of the dilution was adjusted to 9.5 and the osmotic pressure was 200 mOsm/L.
The method comprises the following specific steps: outpatient and inpatient blood is collected, EDTA-K2 is used for anticoagulation, the PLT-I platelet count is obviously reduced, platelet aggregation is found by blood smear microscopy, 20 specimens meeting the EDTA-PTCP diagnostic standard are used as an experimental group, wherein 11 males and 9 females are used, and the average age is 56 years. The blood of a patient with pseudo-aggregated platelets was taken, and after drawing blood without an anticoagulant, the blood was immediately examined on a blood cell analyzer within 1 minute (at which time no aggregation of platelets occurred), and the platelet count value was determined by this method to be the true value PLT _ O (true value) of platelets. Blood was drawn from the patient using an EDTA anticoagulant tube and 2 hours later (the platelets in the pseudoaggregated patient aggregate) was measured on the same hematology analyzer using a diluent containing the disaggregating substance 1-acetylguanidine, and the platelet count value measured in this way was the disaggregation value PLT _ O (disaggregation) of the platelets. Meanwhile, blood was taken from the patient using an EDTA anticoagulant tube, and after 2 hours (the platelets of the pseudoaggregated patient aggregated), the platelet count value measured by this method was the non-disaggregated value PLT _ O (non-disaggregated) of the platelets by the same hematology analyzer without the diluent containing the disaggregating substance 1-acetylguanidine. Calculating the depolymerization effect by the formula:
a depolymerization rate (depolymerization) of PLT _ O (depolymerization)/PLT _ O (true value); or
The depolymerization rate (control) is PLT _ O (not depolymerized)/PLT _ O (true).
The detection results of each sample are shown in fig. 18. As shown in FIG. 18, the pseudoaggregated platelets were disaggregated to various degrees, and in 20 samples, the disaggregation effect reached 70% of the cases after the patient's blood was left for 2 hours. In the control group, the depolymerization effect was 20% or less, and the depolymerization effect of the depolymerization diluent containing 10mM of 1-acetylguanidine was remarkable.
For a sample that is difficult to depolymerize, for example, a sample having a depolymerization rate of 70% or less, a higher concentration may be used, or a compound having a better depolymerization effect may be used, or a compound having an amino group and a compound having an ammonium ion may be used in combination to obtain a desired depolymerization effect.
Test example 5: clinical disaggregation effect of compounds containing ammonium ions on pseudoplatelet aggregation
The test example was to achieve disaggregation of pseudoaggregated platelets in the clinic. The assay was carried out using the same diluent as the diluent a of test example 2. The formula of the diluent is as follows: citric acid (0.5g/L), surfactant phenoxyethanol (0.1g/L), bacteriostatic agent (6g/L), sodium chloride (3g/L),NH4Cl (0.01 mol/L). The pH of the dilution was adjusted to 9.5 and the osmotic pressure was 200 mOsm/L.
The method comprises the following specific steps: outpatient and inpatient blood is collected, EDTA-K2 is used for anticoagulation, the PLT-I platelet count is obviously reduced, platelet aggregation is found by blood smear microscopy, 20 specimens meeting the EDTA-PTCP diagnostic standard are used as an experimental group, wherein 9 males and 8 females are used, and the average age is 51 years. The blood of a patient with pseudo-aggregated platelets was taken, and after drawing blood without an anticoagulant, the blood was immediately examined on a blood cell analyzer within 1 minute (at which time no aggregation of platelets occurred), and the platelet count value was determined by this method to be the true value PLT _ O (true value) of platelets. The blood of the patient was drawn with an EDTA anticoagulant tube and after 2 hours (the platelets of the pseudoaggregated patient would aggregate) was measured on the same hematology analyzer with a diluent containing the disaggregating substance ammonium chloride, and the platelet count value measured in this way was the disaggregation value PLT _ O (disaggregation) of the platelets. Meanwhile, blood was taken from the patient using an EDTA anticoagulant tube, and after 2 hours (the platelets of the pseudoaggregated patient aggregated), the platelet count value measured by this method was the undeployed value PLT _ O (undeployed) of the platelets using the same hematology analyzer without a diluent of ammonium chloride, which is a disaggregation agent. Calculating the depolymerization effect by the formula:
a depolymerization rate (depolymerization) of PLT _ O (depolymerization)/PLT _ O (true value); or
The depolymerization rate (control) is PLT _ O (not depolymerized)/PLT _ O (true).
The detection results of each sample are shown in fig. 19. As shown in the figure, the pseudoaggregated platelets can be disaggregated to different degrees, and in 20 samples, the disaggregation effect of the patient blood after standing for 2 hours still reaches 70% of 13 samples. In the control group, the depolymerization effect was 20% or less, and the depolymerization effect of the depolymerization diluent containing 10mM ammonium chloride was remarkable.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention, and all modifications and equivalents made by the contents of the present specification and drawings, or directly/indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (27)
1. A method of detecting leukocytes in response to interference from platelet aggregation, the method comprising:
subjecting a blood sample to a treatment for preventing and/or eliminating platelet aggregation in the blood sample with a disaggregating agent, wherein the disaggregating agent includes at least one selected from the group consisting of a compound having an amino group and a compound containing an ammonium ion;
and detecting the blood sample treated by the depolymerizing agent by using a blood analyzer so as to obtain at least detection information of the white blood cells.
2. The detection method according to claim 1, wherein the compound having an amino group is selected from the group consisting of compounds represented by the following formula (I) and salts thereof:
R1-NH-R2 (I)
wherein R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, SO, and R1 and R2 are not both H3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkylaryl, substituted or unsubstituted C7-14 arylalkyl, -C (O) -Q1 and-C (O) -O-Q2,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkaryl, or substituted or unsubstituted C7-14 aralkyl;
q2 is H, substituted or unsubstituted C1-16 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-14 alkaryl, or substituted or unsubstituted C7-14 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, halogen, -CN, -C (O) -O-P3, -O-C1-16 alkyl, -O-C6-10 aryl, -O-C7-14 alkylaryl, -O-C7-14 arylalkyl, -C (O) -C1-16 alkyl, -C (O) -C6-10 aryl, -C (O) -C7-14 alkylaryl, -C (O) -C7-14 arylalkyl and-C (O) -NP1P2, wherein said-O-C1-16 alkyl, -O-C6-10 aryl, -O-C7-14 alkaryl, -O-C7-14 aralkyl, -C (O) -C1-16 alkyl, -C (O) -C6-10 aryl, -C (O) -C7-14 alkaryl and-C (O) -C7-14 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH, -NH2、-OH、-SO3H. Halogen, -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of,
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-16 alkyl, C6-10 aryl, C7-14 alkaryl and C7-14 aralkyl, wherein said C1-16 alkyl, C6-10 aryl, C7-14 alkaryl and C7-14 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. Halogen, -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of;
preferably, in said formula (I), R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, -SO, provided that R1 and R2 are not both H at the same time3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, substituted or unsubstituted C7-10 aralkyl, -C (O) -Q1 and-C (O) -O-Q2,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
q2 is H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, -CN, -C (O) -O-P3, -O-C1-10 alkyl, -O-C6-10 aryl, -O-C7-10 alkylaryl, -O-C7-10 arylalkyl, and-C (O) -NP1P2, wherein each of said-O-C1-10 alkyl, -O-C6-10 aryl, -O-C7-10 alkylaryl, and-O-C7-10 arylalkyl is unsubstituted or further substituted with at least one moiety selected from the group consisting of-NH, -CN, -C (O) -O-P3, -O-C1-10 alkyl, -O-C6-aryl, and-O-C7-10 arylalkyl2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of;
p1, P2 and P3 are each independently a group selected from the group consisting of: H. c1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl, wherein said C1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with a group of the group consisting of;
more preferably, in said formula (I), R1 and R2 are the same or different and are each independently a group selected from the group consisting of H, -SO and R1 and R2 are not both H at the same time3H、-NH2、-C(NH)-NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, substituted or unsubstituted C7-10 aralkyl, -C (O) -Q1 and-C (O) -O-H,
wherein Q1 is H, -NH2Substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C7-10 alkaryl, or substituted or unsubstituted C7-10 aralkyl;
wherein said substituted is with at least one moiety selected from the group consisting of-NP 1P2, -SO3H. -OH, -CN, -C (O) -O-H and-C (O) -NP1P 2;
p1 and P2 are each independently a group selected from the group consisting of: H. c1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl, wherein said C1-10 alkyl, C6-10 aryl, C7-10 alkaryl and C7-10 aralkyl are each unsubstituted or further substituted with at least one substituent selected from the group consisting of-NH2、-OH、-SO3H. -CN, -COOH and-C (O) NH2Substituted with groups from the group consisting of.
3. The detection method according to claim 2, wherein the compound of formula (I) has a total number of primary, secondary and/or imine groups of 1 to 20.
4. The detection method according to claim 1, wherein the compound having an amino group has an amino pKa value of 1 to 16, preferably 4 to 14, and more preferably the pH of the reagent is not more than the amino pKa value of the compound having an amino group.
5. The detection method according to claim 1, wherein the concentration of the compound having an amino group in the depolymerization agent is 1 to 50mmol/L, preferably 2 to 20 mmol/L.
6. The detection method according to claim 1, wherein the ammonium ion-containing compound contains an anion selected from the group consisting of chloride, bromide, iodide, hydroxide, phosphate, hydrogen phosphate, dihydrogen phosphate, nitrate, hydrogen sulfide, thiocyanate, sulfate, hydrogen sulfate, sulfite, hydrogen sulfite, carbonate, hydrogen carbonate, formate, acetate, oxalate, propionate, malonate, citrate, and a combination thereof, preferably, the ammonium ion-containing compound is at least one selected from the group consisting of ammonium chloride, ammonium bromide, ammonium iodide, ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate, ammonium nitrate, ammonium hydrogen sulfite, ammonium thiocyanate, ammonium oxalate, ammonium hydroxide, ammonium hydrogen sulfate, and ammonium hydrogen carbonate.
7. The detection method according to claim 1, wherein the concentration of the compound containing ammonium ions in the depolymerization agent is 1 to 50mmol/L, preferably 2 to 20 mmol/L.
8. The detection method according to claim 1, wherein the disaggregating agent comprises at least one compound having an amino group and at least one compound containing an ammonium ion.
9. The detection method according to claim 8, wherein the total concentration of the at least one compound having an amino group and the at least one compound containing an ammonium ion in the depolymerizing agent is 2 to 50mmol/L, preferably 2 to 20mmol/L, and more preferably 2 to 10 mmol/L.
10. The detection method according to claim 8, wherein the molar ratio of the at least one compound having an amino group and the at least one compound containing an ammonium ion is in the range of 10:1 to 1:10, preferably 4:1 to 1: 4.
11. The assay of claim 1, wherein the pH of the blood sample treated with the disaggregating agent is at least 3.0, preferably at least 7.0, more preferably 7.5-11.0.
12. The test method according to claim 1, wherein the blood analyzer comprises an impedance detector, the blood sample is hemolyzed with a red blood cell lysing agent before the test, and the method comprises the steps of:
and detecting the blood sample treated by the depolymerizing agent and the red blood cell cracking agent by using an impedance detector in a blood analyzer to obtain an electric signal of particles in the blood sample, and further obtaining a white blood cell detection parameter after aggregation interference is eliminated.
13. The detection method according to claim 1, wherein the blood analyzer includes an optical detector, the blood sample is subjected to a staining treatment with a fluorescent dye and a hemolysis treatment with a red blood cell lysing agent, and the method includes: detecting the blood sample treated by the depolymerizing agent, the fluorescent dye and the red blood cell cracking agent by using an optical detector in a blood analyzer to obtain at least two optical signals of particles in the blood sample so as to obtain detection information of white blood cells;
preferably, the at least two light signals are selected from the group consisting of fluorescence intensity signals, forward scattered light intensity signals, and side scattered light intensity signals.
14. A reagent for detecting leukocytes in an in vitro blood test, wherein the reagent comprises at least one selected from the group consisting of a compound having an amino group and a compound containing an ammonium ion, a red blood cell lysing agent, a buffer and an osmolality adjusting agent, and optionally a fluorescent dye and/or a surfactant, wherein the concentration of the compound having an amino group is 1 to 50mmol/L, and the concentration of the compound containing an ammonium ion is 1 to 50 mmol/L.
15. The reagent according to claim 14, wherein the compound having an amino group is selected from the group consisting of compounds represented by the following formula (I) and salts thereof:
R1-NH-R2 (I)
wherein the compound of formula (I) is as defined in claim 2.
16. The reagent according to claim 15, wherein the compound of formula (I) has a total number of primary, secondary and/or imine groups of 1 to 20.
17. The reagent according to claim 14, wherein the compound having an amino group has an amino pKa value of 1 to 16, preferably 4 to 14, more preferably the pH value of the reagent is equal to or less than the amino pKa value of the compound having an amino group.
18. The reagent according to claim 14, wherein the concentration of the compound having an amino group is 2 to 20 mmol/L.
19. The reagent according to claim 14, wherein the compound containing ammonium ions is as defined in claim 6.
20. The reagent according to claim 14, wherein the concentration of the compound containing ammonium ions is 2 to 20 mmol/L.
21. The reagent according to claim 14, wherein the reagent comprises at least one compound having an amino group and at least one compound containing an ammonium ion.
22. The reagent according to claim 21, wherein the total concentration of the at least one compound having an amino group and the at least one compound containing an ammonium ion in the reagent is 2 to 50mmol/L, preferably 2 to 20mmol/L, and more preferably 2 to 10 mmol/L.
23. The reagent according to claim 21, wherein the molar ratio of the at least one compound having an amino group and the at least one compound containing an ammonium ion is in the range of 10:1 to 1:10, preferably 4:1 to 1: 4.
24. The reagent according to claim 14, wherein the reagent has a pH of at least 3.0, preferably at least 7.0, more preferably 7.5 to 11.
25. Use of a platelet disaggregation agent in a leukocyte assay, wherein the platelet disaggregation agent is as defined by the disaggregation agent of any one of claims 1 to 10.
26. Use according to claim 25, wherein the platelet depolymerant has a pH of at least 3.0, preferably at least 7.0, more preferably between 7.5 and 11.0.
27. The use of claim 25, wherein the platelet disaggregating agent further comprises a red blood cell lysing agent, a buffer and an osmolality adjusting agent, and optionally a fluorescent dye and/or a surfactant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010702062.2A CN113959912B (en) | 2020-07-20 | 2020-07-20 | Method and reagent for detecting white blood cells for resisting platelet aggregation interference and application of reagent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010702062.2A CN113959912B (en) | 2020-07-20 | 2020-07-20 | Method and reagent for detecting white blood cells for resisting platelet aggregation interference and application of reagent |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113959912A true CN113959912A (en) | 2022-01-21 |
CN113959912B CN113959912B (en) | 2024-06-21 |
Family
ID=79459665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010702062.2A Active CN113959912B (en) | 2020-07-20 | 2020-07-20 | Method and reagent for detecting white blood cells for resisting platelet aggregation interference and application of reagent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113959912B (en) |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529705A (en) * | 1983-06-06 | 1985-07-16 | Coulter Electronics, Inc. | Reagent for combined diluting and lysing whole blood |
CN1030757A (en) * | 1987-06-17 | 1989-02-01 | 伟材株式会社 | Benzothiazole derivant |
CA2140927A1 (en) * | 1992-09-04 | 1994-03-05 | Jeffery A. Zablocki | Platelet aggregation inhibitors |
US5316725A (en) * | 1991-06-07 | 1994-05-31 | Edward Lawrence Carver, Jr. | Reagent system for the improved determination of white blood cell subpopulations |
WO1999036425A1 (en) * | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
WO2001085722A1 (en) * | 2000-05-05 | 2001-11-15 | Cor Therapeutics, Inc. | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
WO2003001968A2 (en) * | 2001-06-26 | 2003-01-09 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
DE102006048300A1 (en) * | 2006-01-26 | 2007-08-02 | Hellstern, Peter, Prof. Dr.med. | New amidinobenzylamino-peptide derivatives, useful as anticoagulant in ex vivo systems, are inhibitors of activated factor X and other enzymes involved in coagulation |
WO2008057601A2 (en) * | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
CN101236195A (en) * | 2007-02-01 | 2008-08-06 | 希森美康株式会社 | Hematological analyzer, method for analyzing body fluid and control system thereof |
CN101750274A (en) * | 2008-12-17 | 2010-06-23 | 深圳迈瑞生物医疗电子股份有限公司 | Differential blood count reagent, kit and method of differential blood count |
CN102320986A (en) * | 2011-07-25 | 2012-01-18 | 武汉武药科技有限公司 | Preparation method for clopidogrel intermediate |
CN102778425A (en) * | 2011-05-10 | 2012-11-14 | 株式会社堀场制作所 | Reagent for blood cell counting and blood analysis method |
CN106525666A (en) * | 2015-09-14 | 2017-03-22 | 希森美康株式会社 | Blood analyzer, blood analyzing method, and information processing apparatus |
CN111356911A (en) * | 2017-11-15 | 2020-06-30 | 雷迪奥米特医学公司 | Platelet activation free heparin-based blood sampler |
CN111656188A (en) * | 2018-04-28 | 2020-09-11 | 深圳迈瑞生物医疗电子股份有限公司 | Reagent, method for analyzing platelet and blood cell analyzer |
-
2020
- 2020-07-20 CN CN202010702062.2A patent/CN113959912B/en active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529705A (en) * | 1983-06-06 | 1985-07-16 | Coulter Electronics, Inc. | Reagent for combined diluting and lysing whole blood |
CN1030757A (en) * | 1987-06-17 | 1989-02-01 | 伟材株式会社 | Benzothiazole derivant |
US5316725A (en) * | 1991-06-07 | 1994-05-31 | Edward Lawrence Carver, Jr. | Reagent system for the improved determination of white blood cell subpopulations |
CA2140927A1 (en) * | 1992-09-04 | 1994-03-05 | Jeffery A. Zablocki | Platelet aggregation inhibitors |
WO1999036425A1 (en) * | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
WO2001085722A1 (en) * | 2000-05-05 | 2001-11-15 | Cor Therapeutics, Inc. | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
WO2003001968A2 (en) * | 2001-06-26 | 2003-01-09 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
DE102006048300A1 (en) * | 2006-01-26 | 2007-08-02 | Hellstern, Peter, Prof. Dr.med. | New amidinobenzylamino-peptide derivatives, useful as anticoagulant in ex vivo systems, are inhibitors of activated factor X and other enzymes involved in coagulation |
WO2008057601A2 (en) * | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
CN101236195A (en) * | 2007-02-01 | 2008-08-06 | 希森美康株式会社 | Hematological analyzer, method for analyzing body fluid and control system thereof |
CN101750274A (en) * | 2008-12-17 | 2010-06-23 | 深圳迈瑞生物医疗电子股份有限公司 | Differential blood count reagent, kit and method of differential blood count |
CN102778425A (en) * | 2011-05-10 | 2012-11-14 | 株式会社堀场制作所 | Reagent for blood cell counting and blood analysis method |
CN102320986A (en) * | 2011-07-25 | 2012-01-18 | 武汉武药科技有限公司 | Preparation method for clopidogrel intermediate |
CN106525666A (en) * | 2015-09-14 | 2017-03-22 | 希森美康株式会社 | Blood analyzer, blood analyzing method, and information processing apparatus |
CN111356911A (en) * | 2017-11-15 | 2020-06-30 | 雷迪奥米特医学公司 | Platelet activation free heparin-based blood sampler |
CN111656188A (en) * | 2018-04-28 | 2020-09-11 | 深圳迈瑞生物医疗电子股份有限公司 | Reagent, method for analyzing platelet and blood cell analyzer |
Non-Patent Citations (4)
Title |
---|
SHUJI KITAGAWA: "Relationship of the effects of nigericin on the aggregation and cytoplasmic pH of bovine platelets in the presence of different cations", vol. 930, pages 48 - 54 * |
刘玉华, 宋玲玲, 吕玉芹: "光学法计数血小板在EDTA依赖的假性血小板减少症中的准确性分析", 中国医疗器械信息, 31 December 2019 (2019-12-31), pages 1 - 2 * |
单春文,梁启兆: "溴苄铵对豚鼠和家兔血小板聚集的影响", 第一军医大学学报, vol. 4, no. 3, 31 December 1984 (1984-12-31), pages 199 - 201 * |
王建昌,张福成, 李颖, 孙晓丽, 刘平: "半胧氨酞一精氨酞一甘氨酞一天冬氨酞一色氨酞一青霉胺对血小板聚集和血栓形成的抑制作用", 中国老年学杂志, vol. 27, 30 June 2007 (2007-06-30), pages 1054 - 1057 * |
Also Published As
Publication number | Publication date |
---|---|
CN113959912B (en) | 2024-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4324552B2 (en) | Leukocyte classification and counting method | |
JP4212827B2 (en) | Bone marrow nucleated cell automatic analysis method | |
JP5362564B2 (en) | Method for measuring cellular hemoglobin | |
EP0598663B1 (en) | A pretreatment method for blood analysis | |
EP0305491B1 (en) | System for isolating and identifying leukocytes | |
US5958776A (en) | Method for classifying and counting immature leukocytes | |
CA1158967A (en) | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes | |
JP3886271B2 (en) | Reagent for classification counting of erythroblast and classification counting method | |
AU775260B2 (en) | Single channel, single dilution detection method | |
EP2324350B1 (en) | Reference control for cell by cell analysis | |
EP1930723B1 (en) | Method for measuring biological sample and measuring apparatus therefor | |
RU2435164C2 (en) | Reagent and set of reagents for analysis of immature leukocytes | |
PL176318B1 (en) | Method of obtaining and stabilising suspensions of blood cells | |
EP2166354B1 (en) | Reagent and reagent kit for analysis of primitive leukocyte | |
CN113959911A (en) | Detection method and reagent for resisting platelet aggregation interference and application thereof | |
CN113959912A (en) | Leukocyte detection method and reagent for resisting platelet aggregation interference and application thereof | |
WO2022016345A1 (en) | Application of composition for platelet disaggregation, disaggregation reagent and disaggregation method | |
WO2022016343A1 (en) | Use of composition for platelet disaggregation, disaggregation reagent, and disaggregation method | |
JP4566299B2 (en) | Classification and counting method of erythroblasts | |
CN112504793B (en) | Reagent for permeating and fixing blood cells and analysis method | |
JP4354982B2 (en) | Leukocyte classification and counting method | |
JP4107441B2 (en) | Reagent for classification counting of erythroblasts | |
CA3138184A1 (en) | Methods and compositions for reversing platelet clumping |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |